Tilray Brands (TLRY) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 11, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	TLRY
Entity Registrant Name	Tilray, Inc.
Entity Central Index Key	0001731348
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38594
Entity Tax Identification Number	82-4310622
Entity Address, Address Line One	1100 Maughan Road
Entity Address, City or Town	Nanaimo
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V9X IJ2
City Area Code	844
Local Phone Number	845-7291
Entity Interactive Data Current	Yes
Title of 12(b) Security	Class 2 Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Class 1 Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		16,666,665
Class 2 Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		108,195,284

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 173,990	$ 96,791
Accounts receivable, net of allowance for credit losses of $595 and provision for sales returns of $1,138 (December 31, 2019 - $615 and $1,400, respectively)	38,324	36,202
Inventory	95,586	87,861
Prepayments and other current assets	31,066	38,173
Total current assets	338,966	259,027
Property and equipment, net	186,970	184,217
Operating lease, right-of-use assets	18,654	17,514
Intangible assets, net	187,892	228,828
Goodwill	150,870	163,251
Equity method investments	8,827	11,448
Other investments	21,250	24,184
Other assets	2,135	7,861
Total assets	915,564	896,330
Current liabilities
Accounts payable	23,907	39,125
Accrued expenses and other current liabilities	47,032	50,829
Accrued lease obligations	3,370	2,473
Senior Facility - current	4,723
Warrant liability	92,339
Total current liabilities	171,371	92,427
Accrued lease obligations	28,538	29,407
Deferred tax liability	48,019	53,363
Convertible notes, net of issuance costs	432,807	430,210
Senior Facility, net of transaction costs	39,106
Other liabilities	5,415	5,652
Total liabilities	725,256	611,059
Commitments and contingencies (refer to Note 17)
Stockholders’ equity
Additional paid-in capital	840,436	705,671
Accumulated other comprehensive (loss) income	(6,988)	9,719
Accumulated deficit	(643,153)	(430,130)
Total stockholders’ equity	190,308	285,271
Total liabilities and stockholders’ equity	915,564	896,330
Class 1 common stock [Member]
Stockholders’ equity
Common stock value	2	2
Class 2 common stock [Member]
Stockholders’ equity
Common stock value	$ 11	$ 9

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts receivable	$ 595	$ 615
Provision for sales returns	$ 1,138	$ 1,400
Class 1 common stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	16,666,665	16,666,665
Common stock, shares outstanding	16,666,665	16,666,665
Class 2 common stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	107,976,818	86,114,560
Common stock, shares outstanding	107,976,818	86,114,560

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 52,102	$ 23,038
Gross profit	10,870	5,385
General and administrative expenses	17,776	12,934
Sales and marketing expenses	17,876	7,821
Research and development expenses	1,258	1,048
Stock-based compensation expenses	7,677	5,736
Depreciation and amortization expenses	3,591	1,865
Impairment of assets	29,839
Acquisition-related expenses, net	2,355	4,424
Loss from equity method investments	1,748
Operating loss	(71,250)	(28,443)
Foreign exchange loss, net	28,069	179
Change in fair value of warrant liability	71,978
Interest expenses, net	9,146	8,744
Finance income from ABG		(135)
Other expense (income), net	4,651	(3,845)
Loss before income taxes	(185,094)	(33,386)
Deferred income tax recoveries	(1,272)	(3,777)
Current income tax expenses (benefit)	301	(240)
Net loss	$ (184,123)	$ (29,369)
Net loss per share - basic and diluted	$ (1.73)	$ (0.31)
Weighted average shares used in computation of net loss per share - basic and diluted	106,463,352	94,875,351
Net loss	$ (184,123)	$ (29,369)
Foreign currency translation loss, net	(16,633)	(475)
Unrealized (loss) gain on available-for-sale debt securities	(74)	19
Other comprehensive loss	(16,707)	(456)
Comprehensive loss	(200,830)	(29,825)
Product Costs [Member]
Cost of sales	37,188	17,329
Inventory Valuation Adjustments [Member]
Cost of sales	$ 4,044	$ 324

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	ABG [Member]	Natura Naturals Inc [Member]	Manitoba Harvest U S L L C [Member]	Common Stock [Member]	Common Stock [Member]ABG [Member]	Common Stock [Member]Natura Naturals Inc [Member]	Common Stock [Member]Manitoba Harvest U S L L C [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]ABG [Member]	Additional Paid-In Capital [Member]Natura Naturals Inc [Member]	Additional Paid-In Capital [Member]Manitoba Harvest U S L L C [Member]	Accumulated Other Comprehensive (loss) Income [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]ABG [Member]
Beginning Balance at Dec. 31, 2018	$ 197,653				$ 10				$ 302,057				$ 3,763	$ (108,177)
Beginning Balance at Dec. 31, 2018					93,170,867
Cumulative effect adjustment from transition to | ASU 2016-01 [Member]													803	(803)
Cumulative effect adjustment from transition to | ASC 842 [Member]	19													19
Shares issued for acquisition		$ 125,097	$ 15,100	$ 96,844						$ 125,097	$ 15,100	$ 96,844
Shares issued for acquisition, shares						1,680,214	180,332	1,209,946
ABG finance receivable, net of finance income	(30,292)								(30,292)
Shares issued under stock-based compensation plans	931								931
Shares issued under stock-based compensation plans, shares					545,000
Shares issued for employee compensation	649								649
Shares issued for employee compensation, shares					11,868
Stock-based compensation expenses	5,736								5,736
Other comprehensive (loss) income	(456)												(456)
Net loss	(29,369)													(29,369)
Ending Balance at Mar. 31, 2019	381,912				$ 10				516,122				4,110	(138,330)
Ending Balance, Shares at Mar. 31, 2019					96,798,227
Beginning Balance at Dec. 31, 2019	285,271				$ 11				705,671				9,719	(430,130)
Beginning Balance at Dec. 31, 2019					102,781,225
Proceeds from ABG Profit Participation Arrangement		$ 1,353								1,353
Write-off of ABG finance receivable										$ 28,900					$ (28,900)
Escrow shares released from downstream merger	(151)								(151)
Escrow shares released shares from downstream merger, shares					(7,659)
Shares issued for common stock at-the-market, net of issuance costs	27,027								27,027
Shares issued for common stock at-the-market, net of issuance costs, shares					2,265,115
Shares issued for acquisition, shares					6,934
Shares issued under stock-based compensation plans	1,079								1,079
Shares issued under stock-based compensation plans, shares					597,868
Stock-based compensation expenses	7,677								7,677
Shares issued under registered offering, net of issuance costs	19,828				$ 1				19,827
Shares issued under registered offering, net of issuance costs, Shares					7,250,000
Shares issued for exercise of pre-funded warrants	49,054				$ 1				49,053
Shares issued for exercise of pre-funded warrants. Shares					11,750,000
Other comprehensive (loss) income	(16,707)												(16,707)
Net loss	(184,123)													(184,123)
Ending Balance at Mar. 31, 2020	$ 190,308				$ 13				$ 840,436				$ (6,988)	$ (643,153)
Ending Balance, Shares at Mar. 31, 2020					124,643,483

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
ABG [Member]
Finance income	$ 2,700

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (184,123)	$ (29,369)
Adjusted for the following items:
Inventory valuation adjustments	4,044	324
Depreciation and amortization expenses	4,561	2,772
Impairment of assets	29,839
Stock-based compensation expenses	7,677	5,736
Change in fair value of warrant liability	71,978
Loss from equity method investments	1,748
Loss (gain) from equity investments measured at fair value	1,534	(1,389)
Loss from sale of investment	65
Interest on debt securities	(221)
Deferred taxes	(1,272)	(3,777)
Amortization of discount on convertible notes	2,597	2,501
Amortization of transaction costs on Senior Facility	131
Foreign currency (gain) loss	28,069	(214)
Accretion related to obligations under finance leases	151	25
Issuance costs on registered offering recorded to net loss	3,953
Credit loss expenses	46	536
Provision for sales returns	(262)
Loss on disposal of property and equipment	457	111
Other non-cash items	138	(322)
Changes in non-cash working capital:
Accounts receivable	(1,906)	3,030
Inventory	(11,594)	(13,307)
Prepayments and other current assets	6,749	(2,143)
Accounts payable	(15,218)	(1,015)
Accrued expenses and other current liabilities	(3,172)	11,660
Net cash used in operating activities	(54,031)	(24,841)
Investing activities
Business combinations, net of cash acquired		(124,140)
Change in deposits and other assets	(927)
Purchases of short-term and other investments		(2,914)
Proceeds from the sale of other investments	437
Purchases of property and equipment	(18,290)	(9,017)
Proceeds from disposal of property and equipment	661
Purchases of intangible assets		(92)
Net cash used in investing activities	(18,119)	(169,496)
Financing activities
Proceeds from at-the-market equity offering, net of costs	27,027
Proceeds from ABG Profit Participation Arrangement	1,353
Proceeds from issuance of registered offering, net of issuance costs	85,465
Payment of ABG finance liability	(1,000)
Proceeds from exercise of stock options	1,813	931
Payment of obligations under finance lease	(105)	(187)
Payment on the settlement of stock options	(748)
Proceeds from issuance of Senior Facility, net of transaction costs	46,395
Repayment of Senior Facility	(414)
Net cash provided by financing activities	159,786	744
Effect of foreign currency translation on cash and cash equivalents	(10,437)	543
Increase (decrease) in cash and cash equivalents	77,199	(193,050)
Cash and cash equivalents, beginning of period	96,791	487,255
Cash and cash equivalents, end of period	$ 173,990	294,205
Investment In ABG [Member]
Investing activities
Investment in ABG Profit Participation Arrangement		$ (33,333)

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Description of the business Tilray, Inc. and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, “our”, or “us”) is a medical cannabis research, cultivation, processing and distribution organization, and is one of the leading suppliers of adult-use cannabis in Canada. The Company also markets and distributes food products from hemp seed, offering a broad range of natural and organic food products and ingredients that are sold through retailers and websites globally. Basis of presentation and going concern The accompanying unaudited condensed consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. These financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due. The Company’s ability to continue as a going concern is dependent upon obtaining additional financing to meet anticipated cash needs for working capital and capital expenditures through the next twelve months. For the three months ended March 31, 2020, the Company reported a consolidated net loss of $184,123 and a net loss of $29,369 for the three months ending March 31, 2019. For the three months ended March 31, 2020, the Company had negative cash flows used in operating activities of $54,031 and negative cash flows used in operating activities of $24,841 for the three months ended March 31, 2019. As at March 31, 2020 and December 31, 2019 the Company had working capital of $167,595 and $166,600, respectively, reflecting an increase of $995 for the three months ended March 31, 2020. Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the additional debt financing of $59,600 secured on February 28, 2020 (refer to Note 12) and net proceeds of $85,289 ($90,439 of gross proceeds) from the registered equity offering on March 17, 2020 (refer to Note 13). The warrants issued as part of the registered offering prohibit the Company’s ability to issue any additional Class 2 common stock prior to receipt of stockholder approval of the anti-dilution price protection feature, at any price lower than $11.90 per share (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events). Unless and until the Company receives stockholder approval of the anti-dilution price protection feature, which will be sought at the Company’s Annual Meeting on May 28, 2020, and not prior to June 30, 2020, subject to certain exceptions or warrant holder consent, the Company is generally prohibited from issuing securities for capital raising purposes (including under the at-the-market offering program) or in connection with mergers and acquisitions. Additionally, assuming approval by the Company’s stockholders and so long as the warrants remain outstanding, the Company may only issue up to $20,000 in aggregate gross proceeds under the Company’s at-the-market offering program at prices less than the exercise price of the warrants (currently $5.95 per share), and in no event more than $6,000 per quarter at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection feature. If the Company’s stockholders do not approve the anti-dilution price protection features, the Company could be prevented from issuing additional securities altogether, which could have a materially adverse effect to the Company’s business. While the Company anticipates receiving approval of the anti-dilution price protection feature at the Annual Meeting of Stockholders on May 28, 2020, at this time, the Company cannot be assured of such approval. On May 4, 2020, the Company submitted an irrevocable 30-day notice for the Additional Draw on the Senior Facility pursuant to the terms of the Senior Facility for $9,900 (refer to Note 12 and Note 25). Due to uncertainties the Company may face in raising additional equity financing in the future, which may be further impacted by the economic downturn and COVID-19, an additional evaluation of management’s forecasts and plans was conducted to assess the Company’s ability to meet its contractual commitments and obligations over the next twelve months. There remains uncertainty given the unprecedented nature of the COVID-19 pandemic and the impact this may have on management’s assumptions used to develop these forecasts. Currently, management’s forecasts support the Company’s ability to meet all covenant compliance and its contractual obligations in the next twelve months such as payment of interest on the 5% convertible notes (refer to Note 11 and Note 17), payment of principal and interest on the Senior Facility (refer to Note 12 and Note 17), non-cancelable minimum purchase commitments for inventory (refer to Note 1 7 ), payment of the ABG finance liability (refer to Note 1 7 ), payment of the Company’s lease commitments (refer to Note 1 7 ) and payment of the Company’s Portugal construction commitments (refer to Note 1 7 ). Should there be additional constraints on access to capital under the at-the-market program, the Company can manage cash-outflows through reduced capital expenditures and managing the operational expenses of the business that pertain to future investments that are discretionary in nature. Accordingly, the Company has concluded it is probable it can implement plans that would effectively mitigate the conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern for the next twelve months. These financial statements do not include any adjustments to the carrying amount and classification of reported assets, liabilities, revenues or expenses that might be necessary should the Company not be successful with the aforementioned initiatives. Any such adjustments could be material. Change in comparative presentation The Company lost its emerging growth company status effective December 31, 2019 and therefore reported as a large accelerated filer in the Annual Financial Statements. As a result, the Company complies with new and revised accounting standards applicable to public companies. In the fourth quarter of 2019, the Company adopted the following accounting pronouncements issued by FASB: ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”); ASU 2016-02, Leases, codified as ASC 842 (“ASC 842”); ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU, codified as ASC 606 (“ASC 606”); and ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), as described in the Annual Financial Statements, with an effective date of January 1, 2019. The comparative three months ended March 31, 2019 included in the financial statements reflects the new and revised accounting standards and therefore does not mirror the March 31, 2019 interim period condensed consolidated financial statements previously filed. The impact to statements of net loss and comprehensive loss for the three months ended March 31, 2019 is as follows: Net loss Other comprehensive (loss) income Unadjusted $ (30,301 ) $ 933 Impact of adoption of accounting standards: ASU 2016-01 1,389 (1,389 ) ASC 842 (27 ) — ASU 2018-07 (430 ) — ASC 606 — — Adjusted $ (29,369 ) $ (456 ) The statement of net loss and comprehensive loss for the three months ended March 31, 2019 was reclassified to conform to the current period’s presentation. Cost of sales, which was formerly presented as a single line item, is now broken out between product costs and inventory valuation adjustments. Loss on disposal of property and equipment, formerly presented in other expenses (income) is now presented in general and administrative expenses. Allowance for credit losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This guidance was subsequently amended by ASU 2018-19, Codification Improvements, ASU 2019-04, Codification Improvements, ASU 2019-05, Targeted Transition Relief, ASU 2019-10, Effective Dates, and ASU 2019-11, Codification Improvements. These ASUs are referred to collectively as the new guidance on current expected credit loss (“CECL”). As a result of the adoption of the new CECL guidance on January 1, 2020, the Company has changed its accounting policy for the allowance for credit losses, as it relates to accounts receivable and available-for-sale debt securities. The adoption of the CECL guidance did not have a material impact on the consolidated financial statements at January 1, 2020. Accounts receivable The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses. The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classes and the expected future loss. This assessment incorporates all available information relevant to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts. As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class. Available-for-sale debt securities The Company assesses its available-for-sale debt securities for impairment at each measurement date. When the fair value is less than the amortized cost, the Company assesses whether it intends to sell the security. When it is assessed that the Company will sell the security or the Company will be required to sell before recovery, the difference between the fair value and amortized cost is recorded as an impairment of assets in the statements of net loss and comprehensive loss. When the Company does not intend to sell and it is not more likely than not that the Company will be required to sell before recovery, the Company assesses whether a portion of the unrealized loss is a result of a credit loss. The Company recognizes the portion related to credit loss as credit loss expenses in general and administrative expenses within the statements of net loss and comprehensive loss and the portion of unrealized loss related to factors other than credit losses in other comprehensive loss. The Company determines the best estimate of the present value of cash flows expected to be collected from the available-for-sale debt securities on an individual basis based on past events, current conditions and forecasts relevant to the individual securities. Disclosure framework - fair value measurement In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) (“ASU 2018-13”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC Topic 820, (b) the policy for timing of transfers between levels, and (c) the valuation process used for Level 3 fair value measurements. ASU 2018-13 also adds, among other items, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The Company adopted ASU 2018-13 effective January 1, 2020 and such adoption did not have a material effect on its financial statements. Warrants In March 2020, the Company closed on a registered offering including Class 2 common stock, warrants and pre-funded warrants (refer to Note 13). As a result, the Company has adopted an accounting policy for warrants. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company's warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each balance sheet date until settlement and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of net loss and comprehensive loss. Transaction costs allocated to warrants that are presented as a liability are expensed immediately within other expenses (income) in the statements of net loss and comprehensive loss. Use of estimates and significant estimates Allowance for credit losses – The Company’s projections of expected credit losses are inherently uncertain, and as a result the Company cannot predict with certainty the amount of such losses. Changes in economic conditions, the risk characteristics and composition of the portfolio, bankruptcy laws, and other factors could impact the actual and projected expected credit losses and the related allowance for credit losses. Actual losses may vary from current estimates. Due to potential COVID-19 disruptions in the marketplace it is possible the Company may experience unforeseen and greater credit losses than anticipated or experienced historically. Warrant liability – The Company estimates the fair value of the warrant liability using a Monte Carlo pricing model. The Company is required to make assumptions and estimates in determining an appropriate risk-free interest rate, volatility, term, dividend yield and discount due to exercise restrictions and fair value of common stock. Net loss per share Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of warrants, stock options, restricted stock units (“RSUs”) and restricted stock awards. In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. As of March 31, 2020, there were 21,266,707 common share equivalents with potential dilutive impact (March 31, 2019 – 8,266,509 ). Since the Company is in a net loss for all periods presented in these financial statements, there is no difference between the Company’s basic and diluted net loss per share for the periods p resented. New accounting pronouncements not yet adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU. In January 2020, the FASB issued ASU 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU.

ABG Profit Participation Arrang

ABG Profit Participation Arrangement	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
ABG Profit Participation Arrangement	2. ABG Profit Participation Arrangement The Company entered into a Profit Participation Arrangement (“ABG Arrangement”) with ABG Intermediate Holdings 2, LLC (“ABG”) on January 14, 2019 as described in the . On January 24, 2020, the Company entered into (i) an Amended and Restated Profit Participation Agreement (the “A&R Profit Participation Agreement”) with ABG, which amended and restated in its entirety the Profit Participation Agreement, dated January 14, 2019, and (ii) the First Amendment to Payment Agreement with ABG (the “Payment Agreement Amendment”), which amends the Payment Agreement, dated January 14, 2019. The Company and ABG agreed that Tilray no longer has any obligation to pay the additional consideration with an aggregate value of $83,333 in cash or in shares of Class 2 common stock. In addition, the Company is not entitled to any guaranteed minimum participation rights and beginning January 1, 2020 through December 31, 2028, the Company agreed that it is not entitled to any participation rights until such participation rights with respect to each contract year exceeds $10,000, and in the event the participation rights are achieved, the Company is entitled to the full 49% participation rights. As a result of entering into the A&R Profit Participation Agreement and the Payment Agreement Amendment, the Company derecognized the ABG finance receivable of $7,011 recorded to impairment of assets through the statements of net loss and comprehensive loss and $28,900 through accumulated deficit in January 2020.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory	3 . Inventory Inventory is comprised of the following items: March 31, 2020 December 31, 2019 Raw materials $ 20,336 $ 15,926 Work-in-process 62,584 53,973 Finished goods 12,666 17,962 Total $ 95,586 $ 87,861 Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following: Three months ended March 31, 2020 2019 Raw materials $ 85 $ — Work-in-process 2,853 324 Finished goods 1,106 — Total $ 4,044 $ 324 During the three months ended March 31, 2020, cannabis products were written down by $3,247 (2019 – $324) and hemp products were written down by $797 (2019 – $0).

Prepayments and Other Current A

Prepayments and Other Current Assets	3 Months Ended
	Mar. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepayments and Other Current Assets	4 . Prepayments and Other Current Assets Prepayments and other current assets are comprised of the following items: March 31, 2020 December 31, 2019 Deposits $ 20,079 $ 25,490 Prepayments 4,376 5,847 Taxes receivable 6,611 6,165 ABG finance receivable - current — 671 Total $ 31,066 $ 38,173

Investments

Investments	3 Months Ended
	Mar. 31, 2020
Investments Debt And Equity Securities [Abstract]
Investments	5 . Investments Other investments Long-term investments are comprised of the following items: March 31, 2020 December 31, 2019 Equity investments at fair value $ 1,838 $ 4,183 Equity investments under measurement alternative 14,232 14,954 Debt securities classified under available-for-sale method 5,180 5,047 Total other investments $ 21,250 $ 24,184 Unrealized losses recognized in other expenses (income) during the three months ended March 31, 2020 on equity investments still held at March 31, 2020 is $1,534 (2019 – gain of $1,396). There were no impairments or adjustments to equity investments under the measurement alternative for the three months ended March 31, 2020 and March 31, 2019. The Company’s debt securities accounted for under the available-for-sale method consists of convertible debt instruments with contractual maturities in 2022. Total unrealized losses of $376 in accumulated other comprehensive income at March 31, 2020 (December 31, 2019 - $302) relates to the long-term available-for-sale debt securities. The Company’s allowance for credit losses on debt securities classified as available-for-sale is $0 at March 31, 2020 (December 31, 2019 – $0) and no related credit loss expenses were recorded during the three months ended March 31, 2020 (March 31, 2019 – $0). Equity method investments As of March 31, 2020, there are no changes to the status of the Company’s assessment of its joint ventures with Anheuser-Busch InBev (“AB InBev”) in Plain Vanilla Research Limited Partnership (“Fluent”) and the Company’s joint venture with Cannfections Group Inc. (“Cannfections”). During the three months ended March 31, 2020, the Company made no capital contributions to Fluent (2019 - $0). The Company provides production support services to Fluent on a cost recovery basis. For the three months ended March 31, 2020, total fees charged were $1,880 (2019 - $0). Total amounts included in accounts receivable is $1,022 at March 31, 2020 (December 31, 2019 - $388). At March 31, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Fluent. During the three months ended March 31, 2020, the Company made no capital contributions to Cannfections (2019 - $0). At March 31, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Cannfections. The Company’s ownership interests in its equity method investments as of March 31, 2020 and December 31, 2019 and loss from equity method investments for the three months ended March 31, 2020 were as follows: Approximate Carrying value Gain (loss) from equity method investments for the three months ended ownership % March 31, 2020 March 31, 2020 Investment in Fluent 50% $ 5,419 $ (1,819 ) Investment in Cannfections 50% 3,408 71 Total equity method investments $ 8,827 $ (1,748 ) Approximate Carrying value Gain (loss) from equity method investments for the three months ended ownership % December 31, 2019 March 31, 2019 Investment in Fluent 50% $ 7,836 $ — Investment in Cannfections 50% 3,612 — Total equity method investments $ 11,448 $ — Summary financial information for the equity method investments on an aggregate basis was as follows: March 31, 2020 December 31, 2019 Current assets $ 11,538 $ 13,942 Noncurrent assets $ 4,525 $ 4,987 Current liabilities $ 3,472 $ 1,561 Noncurrent liabilities $ — $ — Three months ended March 31, 2020 2019 Revenue $ 1,392 $ — Gross profit $ 583 $ — Net loss $ (3,496 ) $ —

Allowance for Credit Losses

Allowance for Credit Losses	3 Months Ended
	Mar. 31, 2020
Allowance For Credit Loss [Abstract]
Allowance for Credit Losses	6. Accounts receivable The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in the existing accounts receivable portfolio as of the reporting dates based on the estimate of expected net credit losses. The following table provides activity in the allowance for credit losses for the three months ended March 31, 2020: Allowance for credit losses, January 1, 2020 $ 615 Provision for expected credit losses (1) 46 Write-offs charged against allowance (19 ) Recoveries of amounts previously written off — Foreign currency translation adjustment (47 ) Allowance for credit losses, March 31, 2020 $ 595 Accounts receivable balance before allowance for credit losses and provision for sales returns, March 31, 2020 $ 40,057 (1) The provision for expected credit losses is recorded in general and administrative expenses Available-for-sale debt securities The Company holds investments in two available-for-sale debt securities, one of which is in an unrealized loss position. The unrealized loss relates to an investment in the convertible debentures of a recreational cannabis company. The investment has been held by the Company for less than twelve months and is deemed not to have a credit loss. The unrealized loss primarily reflects an extended period of general volatility in the cannabis industry, as well as the more recent volatility in the overall economy due to COVID-19. The Company expects to recover the entire amortized cost basis of the security. The Company does not intend to sell the investment and it is not more likely than not that the Company will be required to sell the investment before recovery of its amortized cost basis. The following table provides the fair value and unrealized loss of the investment at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Fair value $ 900 $ 945 Unrealized loss $ 376 $ 302

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, Net	7 . Property and Equipment, Net Property and equipment, net consists of the following: March 31, 2020 December 31, 2019 Land $ 6,117 $ 6,417 Buildings and leasehold improvements 109,413 109,172 Laboratory and manufacturing equipment 31,508 31,173 Office and computer equipment 2,514 2,659 Right-of-use ("ROU") assets under finance lease 13,628 14,753 Construction-in-process, not yet available for use 42,590 37,160 205,770 201,334 Less: accumulated depreciation (18,800 ) (17,117 ) Total $ 186,970 $ 184,217 Refer to Note 17 for contractual commitments related to construction-in-process.

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2020
Goodwill Disclosure [Abstract]
Goodwill	8 . Goodwill The following table shows the change in carrying amount of goodwill: Hemp Cannabis Total Balance as of December 31, 2019 $ 133,314 $ 29,937 $ 163,251 Foreign currency translation adjustment (10,097 ) (2,284 ) (12,381 ) Balance as of March 31, 2020 $ 123,217 $ 27,653 $ 150,870 Goodwill is tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. At March 31, 2020, the Company determined the hemp reporting unit, representing $123,217 of the $150,870 total goodwill, was at risk of having a carrying value exceeding the fair value. As a result, a quantitative test was performed to determine if impairment exists. In performing the Company’s impairment analysis at March 31, 2020, the fair value of the hemp reporting unit was determined primarily by discounting estimated future cash flow, which were determined based on revenue and expense growth assumptions ranging from 9% to 38%, at a weighted average cost of capital (discount rate) ranging from 10% to 12%. The discounted future cash flow model also makes the key assumption that CBD revenue will commence to build in the third quarter of 2021. The fair value of the hemp reporting unit was determined to exceed the carrying value by $76,998, or 26%, and no impairment was recorded. A relatively small change in the underlying assumptions, including a 1% change in the weighted average cost of capital, continued lack of clarity from the Food and Drug Administration regarding approval of CBD or the financial performance of the reporting unit in future years may cause a change in the results of the impairment assessment in future periods and, as such, could result in an impairment of goodwill.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2020
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	9. Intangible assets are comprised of the following items: March 31, December 31, 2020 2019 Cost Accumulated Amortization Impairment Net Cost Accumulated Amortization Impairment Net Definite-lived intangible assets: Patent $ 670 $ 130 $ — $ 540 $ 716 $ 99 $ — $ 617 Customer relationships 125,581 8,565 — 117,016 135,953 7,132 — 128,821 Developed technology 6,535 708 — 5,827 7,074 590 — 6,484 Websites 4,927 3,319 — 1,608 5,157 3,331 — 1,826 Trademarks and licenses 9,014 1,212 6,063 1,739 9,135 925 — 8,210 Total 146,727 13,934 6,063 126,730 158,035 12,077 — 145,958 Indefinite-lived intangible assets: Cultivation license 9,873 — — 9,873 10,689 — — 10,689 Alef license — — — — 4,086 — 4,086 — Trademarks 51,289 — — 51,289 55,416 — — 55,416 Rights under ABG Profit Participation Arrangement 16,765 — 16,765 — 119,366 — 102,601 16,765 Total 77,927 — 16,765 61,162 189,557 — 106,687 82,870 Total intangible assets $ 224,654 $ 13,934 $ 22,828 $ 187,892 $ 347,592 $ 12,077 $ 106,687 $ 228,828 As of March 31, 2020, there are no intangible assets not yet available for use (December 31, 2019 – none). There were no significant additions to intangible assets during the three months ended March 31, 2020. In connection with the preparation of these financial statements, the Company determined that the fair value (Level 3) of indefinite-lived rights under the ABG Profit Participation Arrangement and definite-lived trademarks under the Trademark and License Agreement with ABG for the use of the Prince trademark (“ABG Prince Agreement”) were below the carrying value. The decline in fair value of Rights under ABG Profit Participation Arrangement and ABG Prince Agreement is primarily due to decreased demand projections of CBD products in the United States, resulting in a reduced estimate of future cash flows. As a result, the Company incurred non-cash impairment charges of $16,765 and $6,063 representing the full net book values of the intangible assets relating to the ABG Profit Participation Agreement and ABG Prince Agreement respectively, presented in impairment of assets in the accompanying statements of net loss and comprehensive loss. Amortization expenses for intangibles was $1,857 for the three months ended March 31, 2020 (2019 - $1,558). Expected future amortization expenses for intangible assets as at March 31, 2020 are as follows: Year ending December 31, Amortization 2020 (remaining nine months) $ 7,392 2021 9,557 2022 9,033 2023 8,662 2024 8,658 Thereafter 83,428 Total $ 126,730

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2020
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	10 . Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following items: March 31, 2020 December 31, 2019 Accrued payroll and employment related withholding taxes $ 10,986 $ 24,765 Other accrued expenses and current liabilities 22,297 17,032 Accrued interest on Senior Facility 448 — Accrued interest on convertible notes 11,875 5,938 ABG finance liability - current 875 1,500 Accrued legal and professional fees 158 1,174 Contingent consideration for acquisitions 393 420 Total accrued expenses and other current liabilities $ 47,032 $ 50,829 During the three months ended March 31, 2020, the Company reduced its employee headcount in portions of its global organization to meet the needs of the current industry environment. The Company incurred $1,861 in severance costs, of which $1,580 is included in salaries within general and administrative expenses and $281 is included in cost of sales. Severance costs of $1,424 are allocated to the cannabis reportable segment and $437 are allocated to the hemp reportable segment. As at March 31, 2020, $1,523 was paid to employees and $338 is included in accrued payroll, relating to scheduled benefit payments which were communicated to employees prior to March 31, 2020. Subsequent to March 31, 2020, the Company continued to reduce its employee headcount (refer to Note 25).

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes	1 1 . Convertible Notes In October 2018, the Company issued convertible senior notes with a face value of $475,000 as described in the Annual Financial Statements. As of March 31, 2020, the convertible notes are not yet convertible, and the Company is in compliance with all covenants. The following table sets forth the net carrying amount of the convertible notes: March 31, 2020 December 31, 2019 5.00% Convertible Notes $ 475,000 $ 475,000 Unamortized discount (32,210 ) (34,219 ) Unamortized transaction costs (9,983 ) (10,571 ) Net carrying amount $ 432,807 $ 430,210 The following table sets forth total interest expense recognized related to the convertible notes: Three months ended March 31, 2020 2019 Contractual coupon interest $ 5,938 $ 5,938 Amortization of discount 2,009 1,892 Amortization of transaction costs 588 609 Total $ 8,535 $ 8,439

Senior Facility

Senior Facility	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Senior Facility	12. On February 28, 2020, High Park Holdings Ltd., a wholly owned subsidiary of the Company (“the Borrower”) entered into a credit agreement, denominated in Canadian dollars (“C$”), for a senior secured credit facility in a maximum aggregate principal amount of $59,600 (C$79,800) (the “Senior Facility”). An aggregate principal amount equal to $49,700 (C$66,500) was drawn on February 28, 2020 (the “Closing Date Draw”) and $9,900 (C$13,300) may be drawn at any point after May 28, 2020 (90 days following closing) at the Company’s election (the “Additional Draw”). The Senior Facility bears interest on the outstanding principal balance at an annual rate equal to the Canadian prime rate plus 8.05%, calculated based on the daily outstanding balance of the Senior Facility calculated and compounded monthly in arrears and with no deemed reinvestment of monthly payments. Interest is due monthly throughout the term. The Closing Date Draw principal repayments of $394 (C$554) are due monthly which will result in an aggregate balance of $37,788 (C$53,200) due at February 28, 2022. The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice. Transaction costs incurred on the Closing Date Draw were $3,306 (C$4,425). If the Company elects to exercise the Additional Draw it will incur transaction costs of $567 (C$798), payable only at the date of the Additional Draw. Transaction costs are deferred and amortized as a component of interest expense over the estimated term using the effective interest rate method. The Senior Facility has first priority claims on all North American assets of the Company and contains certain affirmative and negative covenants. The operational covenant includes a minimum unrestricted cash threshold of $28,412 (C$40,000) in order for the Company to make additional capital expenditures and investments. The Senior Facility is collateralized against all real and personal property owned, leased and operated by the Company in North America, and any and all other property of the Company now existing and acquired in North America after the closing date. As of March 31, 2020, the Company was in compliance with all covenants set forth under the Senior Facility. On May 4, 2020, the Company submitted an irrevocable 30-day notice for the Additional Draw, pursuant to the terms of the Senior Facility (refer to Note 25). The following table sets forth the net carrying amount of the Senior Facility: March 31, 2020 Senior Facility $ 46,841 Unamortized transaction costs (3,012 ) Net carrying amount $ 43,829 Less: current portion of Senior Facility (4,723 ) Total noncurrent portion of Senior Facility $ 39,106 The following table sets forth total interest expense recognized related to the Senior Facility: Three months ended March 31, 2020 Contractual interest at Canadian prime plus 8.05% $ 480 Amortization of transaction costs 131 Total $ 611

Warrants

Warrants	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Registered Offering and Warrants	13. Registered Offering and Warrants On March 17, 2020 the Company closed a registered offering of 7,250,000 shares of the Company’s Class 2 common stock for $4.76 per share with an equal number of accompanying warrants and 11,750,000 pre-funded warrants for $4.7599 (the “pre-funded warrants”) with an equal number of accompanying warrants. The pre-funded warrants have an exercise price per share of Class 2 common stock of $0.0001 and are exercisable at any time after their original issuance and expire on the fifth anniversary date of issuance. The 19,000,000 total a ccompanying warrants (the “warrants”) allow the holder s to purchase an aggregate of 19,000,000 shares of the Company’s Class 2 common stock. The warrants have an exercise price per share of Class 2 common stock of $ 5.95 and are exercisable at any time after the first trading day following the six-month anniversary of the issuance and will expire on the fifth anniversary date from the date they become exercisable . The total gross proceeds of the registered offering was $90,439, of which $21,025 was allocated to the Class 2 common stock at the offering close and $69,414 was allocated to the warrant liability. Issuance costs incurred on the registered offering was $5,150, of which $3,953 was recorded to other expenses (income) in the statements of net loss and comprehensive loss and $1,197 was allocated to the Class 2 common stock and recorded net against the allocated gross proceeds in additional paid-in-capital. The pre-funded warrants and warrants contain anti-dilution price protection features, subject to stockholder approval, which adjust the exercise price of pre-funded warrants and warrants if the Company subsequently issues Class 2 common stock at a price lower than the exercise price of the pre-funded warrants and warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the pre-funded warrants and warrants will be adjusted accordingly. At March 31, 2020, the anti-dilution price protection features remain subject to stockholder approval at the Company’s Annual Stockholders’ Meeting on May 28, 2020 and there are no triggering events during the three months ended March 31, 2020. The Company's pre-funded warrants and warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, an event outside the control of the Company. The holders, at their sole discretion, may elect to effect a cashless exercise, and be issued un-registered shares in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of Class 2 common stock due to be issued multiplied by any trading price of the Class 2 common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered Class 2 common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise. Pre-funded warrants and warrants outstanding at March 31, 2020, and related activity for the three months ended March 31, 2020 is as follows (reflects the number of Class 2 common stock as if the warrants were converted to Class 2 common stock): Description Classification Exercise price Expiration date Balance December 31, 2019 Issued Exercised Balance March 31, 2020 Pre-Funded Warrants Liability $ 0.0001 March 17, 2025 — 11,750,000 (11,750,000 ) — Warrants Liability $ 5.95 March 17, 2025 — 19,000,000 — 19,000,000 Total — 30,750,000 (11,750,000 ) 19,000,000 Risk-free interest rate 0.94 % Expected volatility 118 % Expected term 5.5 years Expected dividend yield 0 % Strike price $ 5.95 Fair value of common stock $ 6.88 Discount due to exercise restrictions 17 % Expected volatility is based on the historical volatility of the Company's common stock since its initial public offering in 2018.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	1 4 . Stockholders’ Equity Common and preferred stock The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of March 31, 2020. The liquidation and dividend rights are identical among Class 1 common stock and Class 2 common stock, and all classes of common stock share equally in the Company’s earnings and losses. Par Value Authorized Voting Rights Class 1 common stock $ 0.0001 250,000,000 10 votes for each share Class 2 common stock $ 0.0001 500,000,000 1 vote for each share Preferred stock $ 0.0001 10,000,000 N/A On March 17, 2020 the Company closed the registered offering, issuing 7,250,000 shares of the Company’s Class 2 common stock along with pre-funded warrants and warrants (refer to Note 13). During the period from the close of the registered offering and March 31, 2020, all pre-funded warrants were exercised at a price per share of $ 0.0001 and the Company issued 11,750,000 Class 2 common stock (refer to Note 1 3 ). During the three months ended March 31, 2020, the Company issued 2,265,115 shares of Class 2 common stock for gross proceeds of $27,579 under the at-the-market equity offering. Transaction costs of $552 were recorded net against the allocated gross proceeds in additional paid-in-capital. The warrants issued as part of the registered offering prohibit the Company from issuing any additional Class 2 common stock prior to receipt of stockholder approval of the anti-dilution price protection features, at any price lower than $11.90 per share (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events). Unless and until the Company receives stockholder approval, which will be sought at the Company’s Annual Meeting on May 28, 2020, of the anti-dilution price protection feature and not prior to June 30, 2020, subject to certain exceptions or warrant holder consent, the Company is generally prohibited from issuing securities for capital raising purposes (including under the at-the-market offering program) or in connection with mergers and acquisitions. Additionally, assuming approval by the Company’s stockholders and so long as the warrants remain outstanding, the Company may only issue up to $20,000 in aggregate gross proceeds under the Company’s at-the-market offering program at prices less than the exercise price of the warrants, and in no event more than $6,000 per quarter, at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection features. If the Company’s stockholders do not approve the anti-dilution price protection features, the Company could be prevented from issuing additional securities altogether, which could have a materially adverse effect to our business. While the Company anticipates receiving approval of the anti-dilution price protection features at the Stockholders’ Annual Meeting on May 28, 2020, the Company cannot be assured of such approval. The Company’s future ability to pay cash dividends on Class 2 common stock is limited by the terms of the Senior Facility and cannot be paid without the consent of the lender.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	1 5 . Stock-based Compensation Original Stock Option Plan Certain employees of the Company participate in the equity-based compensation plan of Privateer Holdings, Inc. (the “Original Plan”) under the terms and valuation method detailed in our annual financial statements. For the three months ended March 31, 2020, the total stock-based compensation expense associated with the Original Plan was $162 (2019 – $110). As of March 31, 2020 the total remaining unrecognized stock-based compensation expense related to non-vested stock options under the Original Plan amounted to $676 which will be recognized over the weighted-average remaining requisite service period of approximately 0.8 years. Stock option activity under the Original Plan is as follows: Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 3,014,004 $ 3.04 5.8 $ 44,108 Exercised (217,982 ) 0.27 Forfeited (36,612 ) 4.21 Cancelled (3,197 ) 4.44 Balance March 31, 2020 2,756,213 $ 3.20 5.6 $ 39,680 Vested and expected to vest, March 31, 2020 2,742,644 $ 3.18 5.6 $ 39,525 Vested and exercisable, March 31, 2020 2,563,446 $ 3.00 5.4 $ 37,319 No stock options were granted under the Original Plan during the three months ended March 31, 2020 and March 31, 2019. The total fair value of stock options vested as of March 31, 2020 was $169 (2019 – $95). New Stock Option and Restricted Stock Unit Plan The Company adopted the as amended and approved by stockholders in May 2018 under . For the three months ended March 31, 2020, total stock-based compensation expense associated with the 2018 EIP was $ 7,515 (2019 - $ 5,626 ). As of March 31, 2020, the total remaining unrecognized s tock-based compensation expense related to non-vested stock options and restricted stock units (“RSUs”) under the 2018 EIP amounted to $ 58,318 which will be recognized over the weighted average remaining requisite service period of approximately 1.94 years . Stock option and RSU activity under the 2018 EIP are as follows: Time-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 5,307,130 $ 14.04 8.4 $ 44,297 Granted — — Exercised (169,817 ) 7.76 Forfeited (95,340 ) 17.04 Cancelled (5,596 ) 62.32 Balance March 31, 2020 5,036,377 $ 14.14 8.1 $ — Vested and expected to vest, March 31, 2020 4,863,171 $ 13.93 8.1 $ — Vested and exercisable, March 31, 2020 2,707,014 $ 12.29 8.1 $ — During the three months ended March 31, 2020 , no time-based stock options were granted under the 2018 EIP (2019 – 10,000). The weighted-average fair values of stock options granted during the three months ended March 31, 2020 was $0 per share (2019 – $45.67). Performance-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 520,000 $ 7.76 8.4 $ 4,872 Granted — — — Exercised — — Forfeited — — — Cancelled — — — Balance March 31, 2020 520,000 $ 7.76 8.1 $ — Vested and expected to vest, March 31, 2020 520,000 $ 7.76 8.1 $ — Vested and exercisable, March 31, 2020 520,000 $ 7.76 8.1 $ — No performance-based stock options were granted under the 2018 EIP during the three months ended March 31, 2020 and March 31, 2019. The total fair value of stock options vested as of March 31, 2020 was $0 (2019– $955). Time-based RSU activity Time-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 1,423,392 $ 42.05 Granted 752,283 11.20 Vested (154,642 ) 55.92 Forfeited (186,454 ) 45.27 Non-vested March 31, 2020 1,834,579 $ 27.90 During the three months ended March 31, 2020, 752,283 (2019 – 320,351) time-based RSUs were granted. During the three months ended March 31, 2020, 154,642 (2019 – none) time-based RSUs vested. Performance-based RSUs activity Performance-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 265,625 $ 7.76 Vested (53,125 ) 7.76 Non-vested March 31, 2020 212,500 $ 7.76 No performance-based RSUs were granted during the three months ended March 31, 2020 (2019 – none). During the three months ended March 31, 2020, 53,125 (2019 – 425,000) performance-based RSUs vested .

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income (AOCI)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income (“AOCI”)	1 6 . Accumulated Other Comprehensive (Loss) Income (“AOCI”) The components of AOCI, net of tax, were as follows: Foreign Currency Translation Adjustments Unrealized (loss) gain on available-for-sale debt securities Total Balance as at December 31, 2019 $ 10,021 $ (302 ) $ 9,719 Other comprehensive loss: Change in foreign currency translation (16,633 ) — (16,633 ) Change in unrealized losses on available-for-sale debt securities — (74 ) (74 ) Balance as at March 31, 2020 $ (6,612 ) $ (376 ) $ (6,988 )

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	1 7 . Commitments and Contingencies Legal proceedings In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. The Company records a loss contingency if the information available indicates that it is probable that a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. In the opinion of management, such claims do not meet the criteria to record a loss contingency. Lease commitments The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2027. Maturities of lease liabilities: Year ending December 31, Operating Leases Finance Leases 2020 (remaining nine months) $ 2,799 $ 614 2021 3,025 798 2022 2,944 5,686 2023 2,844 11,545 2024 2,443 — Thereafter 7,801 — Total lease payments $ 21,856 $ 18,643 Imputed interest 3,161 5,430 Obligations recognized $ 18,695 $ 13,213 Purchase commitments The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of March 31, 2020: Total 2020 (remaining nine months) 2021 2022 2023 2024 Thereafter Purchase commitments $ 113,047 $ 111,445 $ 1,530 $ 36 $ 36 $ — $ — Total $ 113,047 $ 111,445 $ 1,530 $ 36 $ 36 $ — $ — As a result of changing industry dynamics, the Company is currently in the process of re-negotiating the terms of several supply agreements, including quantities and pricing, related to cannabis CBD, cannabis extracts/oils, and hemp flower. The re-negotiations are ongoing and there can be no assurance that terms satisfactory to the Company can be reached on a timely basis, or at all. In 2018, the Company signed an agreement with Rose Lifescience Inc. (“Rose”) for distribution and marketing of product in Quebec in exchange for a minimum fee of $384 per annum for an initial term of five years. The Company has agreed to purchase the lesser of 2,000 Kg per year or 40% of the production of Cannabis at a rate of 115% of cost of goods sold from the Rose facility. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule. In 2018, the Company entered into a Product and Trademark License Agreement with Docklight LLC, a related party (refer to Note 21), to use certain intellectual property rights in exchange for payment of royalty depending upon specified percentage of licensed product net sales. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule. Other commitments The Company has payments on the ABG finance liability (refer to Note 10), convertible notes (refer to Note 11) and the Senior Facility (refer to Note 12) as follows: Total 2020 (remaining nine months) 2021 2022 2023 2024 Thereafter ABG finance liability $ 8,000 $ 500 $ 1,500 $ 1,500 $ 1,500 $ 1,500 $ 1,500 Convertible notes, principal and interest 570,000 23,750 23,750 23,750 498,750 — — Senior Facility, principal and interest 55,765 7,918 9,001 38,846 — — — Portugal construction commitments 17,423 17,423 — — — — — Total $ 651,188 $ 49,591 $ 34,251 $ 64,096 $ 500,250 $ 1,500 $ 1,500

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customers	1 8 . Revenue from Contracts with Customers The Company reports two segments: cannabis and hemp, in accordance with ASC 280 Segment Reporting. The Company generates revenues from the cannabis and hemp segments through contracts with customers, each with a single performance obligation, being the sale of products. The Company determines that revenue information disclosed in business segment information in Note 24 disaggregates revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. For certain long-term arrangements, the Company has performance obligations for goods it has not yet delivered. For these arrangements, the Company does not have a right to bill for the undelivered goods. The Company has determined that any unbilled consideration relates entirely to the value of undelivered goods. Accordingly, the Company has not recognized revenue, and has elected not to disclose amounts, related to these undelivered goods. As of March 31, 2020 and December 31, 2019, other than accounts receivable, net of allowance for credit losses and provision for sales returns, the Company has no contract balances in the balance sheets.

General and Administrative Expe

General and Administrative Expenses	3 Months Ended
	Mar. 31, 2020
General And Administrative Expense [Abstract]
General and Administrative Expenses	1 9 . General and Administrative Expenses General and administrative expenses are comprised of the following items: Three months ended March 31, 2020 2019 Salaries $ 7,296 $ 6,411 Professional fees 4,521 2,457 Travel expenses 963 721 Other expenses 4,493 2,698 Credit loss expenses 46 536 Loss on disposal of property and equipment 457 111 Total $ 17,776 $ 12,934

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	20 . Supplemental Cash Flow Information Three months ended March 31, 2020 2019 Cash paid for interest $ 704 $ 73 Non-cash financing activities Shares issued for employee compensation $ — $ 649 Non-cash investing Acquisition of Manitoba Harvest $ — $ 195,407 Acquisition of Natura $ — $ 38,980 Investment in ABG Profit Participation Arrangement, net of receivable $ — $ 94,805 Three months ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 854 $ 247 Operating cash flows from finance leases $ 142 $ — Financing cash flows from finance leases $ 105 $ — Non-cash additions to Right-of-use assets and lease liabilities Operating leases $ 423 $ 3,431 Finance leases $ — $ —

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	2 1 . Related Party Transactions In the normal course of business, the Company enters into related party transactions with certain entities under common control and joint ventures as described in the Annual Financial Statements and detailed below. Leafly Holdings, Inc. (“Leafly”) The Company has a series of agreements with Leafly providing for, among other things, data licensing, advertising and marketing activities. During the three months ended March 31, 2020, operational expenses of $129 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $0). Docklight LLC (“Docklight”) The Company pays Docklight a royalty fee pursuant to a brand licensing agreement which provides the Company with exclusive rights in Canada for the use of certain adult-use brands. During the three months ended March 31, 2020, royalty fees of $221 were recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $59). Refer to Note 17 for purchase commitments with Docklight. Ten Eleven Management LLC (“Ten Eleven”) In January 2020 the Company entered into a management agreement with Ten Eleven Management LLC (“Ten Eleven”) for a four-month term ending April 30, 2020, pursuant to which Ten Eleven provides the Company with certain general administrative and corporate services on an as-requested basis for a monthly service fee. During the three months ended March 31, 2020, management services of $53 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $50). The Company sub-leases a portion of certain office space to Ten Eleven. Ten Eleven’s lease payments are based on the pro-rata share of space that they occupy, with annual lease payments of $470. The sub-lease currently expires in December 2020 Fluent and Cannfections The Company has joint venture arrangements with a 50% ownership and voting interest in each Fluent and Cannfections. Refer to Note 5 for details over transactions with these entities for the three months ended March 31, 2020. Aircraft Time Share Reimbursement The Company had entered into an aircraft time-share agreement and a lease consent and subordination agreement with Brendan Kennedy, our Chief Executive Officer, whereby the Company has access to and use of an aircraft owned by Mr. Kennedy on an as-needed basis for business purposes. Pursuant to this arrangement, the Company reimburses Mr. Kennedy for certain related aircraft expenses. For the three months ended March 31, 2020, the Company incurred $261 of fees which is included in general and administrative expenses (2019 – $0). Accounts payable due to related parties At March 31, 2020, the Company has accounts payable due to related parties of $748 (December 31, 2019 - $68).

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2020
Investments All Other Investments [Abstract]
Financial Instruments	2 2 . Financial Instruments Credit risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents are deposited in major financial institutions in Canada, Australia, Portugal, Germany and the United States. To date, the Company has not experienced any losses on its cash deposits. Accounts receivable are unsecured and the Company does not require collateral from its customers. The Company is also exposed to credit risk from the potential default by any of its counterparties on its financial assets. The Company evaluates the collectability of its accounts receivable and provides an allowance for credit losses as necessary (refer to Note 6). Due to the uncertainties associated with COVID-19, the Company may be unable to accurately predict the creditworthiness of its counterparties and their ability to meet their obligations. This may result in unforeseen additional credit losses. Foreign currency risk The Company conducts its business in several countries and in a variety of currencies, the most significant of which are Canada and the Canadian dollar and the Euro. Consequently, the Company is exposed to foreign currency risk. A significant portion of the Company’s assets, liabilities, revenue, and expenses are denominated in Canadian dollars. A 10% change in the exchange rates for the Canadian dollar would affect the carrying value of net assets by approximately $25,465 as of March 31, 2020, with a corresponding impact to accumulated other comprehensive (loss) income. The Company is also exposed to risk related to changes in the value of the Euro’s due to its one construction commitment in Portugal. Interest rate risk The Company’s exposure to changes in interest rates relates primarily to the Company’s outsanding debt. The Company is exposed to changes to the Canadian prime rate as the Senior Facility bears interest based on the Canadian prime rate plus 8.05%. The convertible notes bear interest at a fixed rate of 5% and are not publicly traded and is therefore are not affected by changes in the market interest rates. A 1% change in the Canadian prime rate would have an impact of $44 to the statements of net loss and comprehensive loss for the three months ended March 31, 2020. Liquidity risk The Company’s objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash flows generated from operations to meet its requirements. As of March 31, 2020, the most significant financial liabilities are accounts payable, accrued expenses and other current liabilities, convertible notes and the Senior Facility.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	2 3 . Fair Value Measurement The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total March 31, 2020 Investments Equity investments measured at fair value $ 1,838 $ — $ — $ 1,838 Debt securities classified as available-for-sale 639 — 4,541 5,180 Acquisition-related contingent consideration — — (393 ) (393 ) Warrant liability — — (92,339 ) (92,339 ) Total recurring fair value measurements $ 2,477 $ — $ (88,191 ) $ (85,714 ) Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2019 Investments Equity investments measured at fair value $ 4,183 $ — $ — $ 4,183 Debt securities classified as available-for-sale 727 — 4,320 5,047 Acquisition-related contingent consideration — — (420 ) (420 ) Total recurring fair value measurements $ 4,910 $ — $ 3,900 $ 8,810 Items measured at fair value on a recurring basis The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration and warrant liability. Debt securities classified as available-for-sale and equity investments recorded at fair value: The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows. Acquisition-related contingent consideration: Contingent consideration is recorded in accrued expenses and other current liabilities and reflects the fair value of consideration related to the acquisition of Smith & Sinclair that may have to be paid if certain revenue targets are met during 2020, as well as targets related to the launch of CBD products in the United States and Europe, and THC products in Canada by 2020. Significant increases (decreases) in the expected revenue levels or in any of the probabilities of achieving the established milestones, or decreases (increases) in the discount rate, would result in a significantly higher (lower) fair values associated with the contingent consideration. The contingent consideration is reassessed and adjusted to fair value at each reporting date in acquisition-related (income) expense, net. Warrant liability: The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Monte Carlo pricing model (refer to Note 13). The warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity. The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows: Debt securities classified as available-for- sale Acquisition- related contingent consideration Warrant liability Opening balance as at December 31, 2019 $ 4,320 $ (420 ) $ — Additions and settlements Additions — — (69,414 ) Exercise — — 49,053 Total gains or losses for the period: — — — Included in net loss — — — Interest expenses, net 221 — — Change in fair value of warrant liability — — (71,978 ) Foreign currency translation loss, net — 27 — Closing balance as at March 31, 2020 $ 4,541 $ (393 ) $ (92,339 ) Quantitative information about Level 3 fair value measurements Fair value at March 31, 2020 Valuation technique Unobservable input Range (weighted average) Discount rate 16.5% Debt securities classified as available-for-sale $ 4,541 Discounted cash flow Probability of conversion/ prepayment nil Probability of default nil Acquisition-related contingent consideration $ (393 ) Discounted cash flow Discount rate 15% Assumed likelihood of milestone payments 50% - 90% Volatility 118% Warrant liability $ (92,339 ) Monte Carlo Restriction 17% Expected life 0.5 years to 5.5 years (2.5 years) Items measured at fair value on a non-recurring basis The Company's prepayments and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. In connection with an evaluation of such assets during the three months ended March 31, 2020, the carrying values of the ABG finance receivable and certain intangible assets were concluded to exceed their fair values. As a result, the Company recorded impairment charges that incorporates fair value measurements based on Level 3 inputs (refer to Note 2 and Note 9). The estimated fair value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other current liabilities, convertible notes and Senior Facility at March 31, 2020 (December 31, 2019 – the fair value of all aforementioned, except the Senior Facility which was entered into in 2020) approximate their carrying value .

Business Segment Information

Business Segment Information	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Business Segment Information	2 4 . Business Segment Information The Company has two operating segments based on major product categories: cannabis and hemp. These operating segments are also the Company’s reportable segments. The cannabis segment cultivates, processes and distributes medical and adult-use cannabis products in a variety of formats, as well as related accessories, on a global basis. The hemp segment processes and distributes a diverse portfolio of hemp-based natural and organic food and wellness products within North America. The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and gross profit as the measure of segment profit or loss. The accounting policies of each segment are the same as those set out under the summary of significant accounting policies in Note 1. There are no intersegment sales or transfers. The comparative three months ended March 31, 2019 have been recast to reflect to the current segment structure. Three months ended March 31, 2020 2019 Revenue Gross profit Revenue Gross profit Cannabis $ 30,776 $ 2,926 $ 17,456 $ 3,621 Hemp $ 21,326 $ 7,944 $ 5,582 $ 1,764 Total $ 52,102 $ 10,870 $ 23,038 $ 5,385 No asset information is provided for the segments because the Company’s chief operating decision maker does not review this information by segment on a regular basis. Total revenue and gross profit for the reportable segments is equal to the Company’s consolidated revenue and gross profit. Three months ended March 31, 2020 2019 Gross profit for the segments $ 10,870 $ 5,385 General and administrative expenses 17,776 12,934 Sales and marketing expenses 17,876 7,821 Research and development expenses 1,258 1,048 Depreciation and amortization expenses 3,591 1,865 Stock-based compensation expense 7,677 5,736 Impairment of assets 29,839 — Acquisition-related expenses, net 2,355 4,424 Loss from equity method investments 1,748 — Foreign exchange loss, net 28,069 179 Change in fair value of warrant liability 71,978 — Interest expenses, net 9,146 8,744 Finance income from ABG — (135 ) Other expense (income), net 4,651 (3,845 ) Loss before income taxes $ (185,094 ) $ (33,386 ) Sources of revenue were as follows: Three months ended March 31, 2020 2019 Dried cannabis $ 19,696 $ 10,936 Cannabis extracts 10,545 6,454 Hemp products 21,326 5,582 Accessories and other 535 66 Total $ 52,102 $ 23,038 Channels of revenue were as follows: Three months ended March 31, 2020 2019 Cannabis Adult-use $ 20,919 $ 7,880 Canada - medical 4,051 2,998 International - medical 5,806 1,811 Bulk — 4,767 Total Cannabis revenue $ 30,776 $ 17,456 Hemp 21,326 5,582 Total $ 52,102 $ 23,038 Revenue attributed to geographic region based on the location of the customer was as follows: Three months ended March 31, 2020 2019 Canada $ 29,488 $ 17,002 United States 16,530 4,225 Other countries 6,084 1,811 Total $ 52,102 $ 23,038 Long-lived assets consisting of property and equipment, net of accumulated depreciation, attributed to geographic regions based on their physical location were as follows: March 31, 2020 December 31, 2019 Canada $ 131,915 $ 144,065 Portugal 50,069 36,908 United States 4,824 3,171 Other countries 162 73 Total $ 186,970 $ 184,217 Three customers accounted for 26%, 16%, and 13% of revenue, respectively, for the three months ended March 31, 2020. One customer accounted for 13% of the Company’s revenue for the three months ended March 31, 2019 Two customers accounted for 18% and 12%, respectively, of the Company’s accounts receivable balance as of March 31, 2020. Two customers accounted for 20% and 10%, respectively, of the Company’s accounts receivable balance as of December 31, 2019.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	25. Subsequent Subsequent to March 31, 2020, the Company continued to reduce its employee headcount and incurred an additional $466 in severance costs, partly in response to the volatile economic environment. All of the additional severance costs relate to the cannabis reportable segment. Management continues to evaluate its cost structure and may take further actions in the future and incur additional related costs. On March 25, 2020, the Board of Directors of the Company unanimously approved the pro rata release of 11,000,000 shares of Class 2 common stock held by the former equity holders of Privateer Holdings, Inc. (“Privateer Holdings”). The shares were released from lock-up agreements entered under the Downstream Merger completed on December 12, 2019, as described in the Annual Financial Statements. The waiver and release took effect on April 3, 2020, and the released shares may be sold on or after that date, subject to applicable securities law or contractual limitations. On May 4, 2020, the Company submitted an irrevocable 30-day notice for the Additional Draw (refer to Note 12), pursuant to the terms of the Senior Facility (refer to Note 12), which will provide the Company an additional $9,900 (C$13,300) financing on June 3, 2020. The Additional Draw will incur transaction costs of $567 (C$798), payable on receipt of the financing and will increase monthly principal payments by $83 (C$111) with the remaining principal balance due in full upon maturity on February 28, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Description of the Business	Description of the business Tilray, Inc. and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, “our”, or “us”) is a medical cannabis research, cultivation, processing and distribution organization, and is one of the leading suppliers of adult-use cannabis in Canada. The Company also markets and distributes food products from hemp seed, offering a broad range of natural and organic food products and ingredients that are sold through retailers and websites globally.
Basis of Presentation and Going Concern	Basis of presentation and going concern The accompanying unaudited condensed consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. These financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due. The Company’s ability to continue as a going concern is dependent upon obtaining additional financing to meet anticipated cash needs for working capital and capital expenditures through the next twelve months. For the three months ended March 31, 2020, the Company reported a consolidated net loss of $184,123 and a net loss of $29,369 for the three months ending March 31, 2019. For the three months ended March 31, 2020, the Company had negative cash flows used in operating activities of $54,031 and negative cash flows used in operating activities of $24,841 for the three months ended March 31, 2019. As at March 31, 2020 and December 31, 2019 the Company had working capital of $167,595 and $166,600, respectively, reflecting an increase of $995 for the three months ended March 31, 2020. Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the additional debt financing of $59,600 secured on February 28, 2020 (refer to Note 12) and net proceeds of $85,289 ($90,439 of gross proceeds) from the registered equity offering on March 17, 2020 (refer to Note 13). The warrants issued as part of the registered offering prohibit the Company’s ability to issue any additional Class 2 common stock prior to receipt of stockholder approval of the anti-dilution price protection feature, at any price lower than $11.90 per share (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events). Unless and until the Company receives stockholder approval of the anti-dilution price protection feature, which will be sought at the Company’s Annual Meeting on May 28, 2020, and not prior to June 30, 2020, subject to certain exceptions or warrant holder consent, the Company is generally prohibited from issuing securities for capital raising purposes (including under the at-the-market offering program) or in connection with mergers and acquisitions. Additionally, assuming approval by the Company’s stockholders and so long as the warrants remain outstanding, the Company may only issue up to $20,000 in aggregate gross proceeds under the Company’s at-the-market offering program at prices less than the exercise price of the warrants (currently $5.95 per share), and in no event more than $6,000 per quarter at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection feature. If the Company’s stockholders do not approve the anti-dilution price protection features, the Company could be prevented from issuing additional securities altogether, which could have a materially adverse effect to the Company’s business. While the Company anticipates receiving approval of the anti-dilution price protection feature at the Annual Meeting of Stockholders on May 28, 2020, at this time, the Company cannot be assured of such approval. On May 4, 2020, the Company submitted an irrevocable 30-day notice for the Additional Draw on the Senior Facility pursuant to the terms of the Senior Facility for $9,900 (refer to Note 12 and Note 25). Due to uncertainties the Company may face in raising additional equity financing in the future, which may be further impacted by the economic downturn and COVID-19, an additional evaluation of management’s forecasts and plans was conducted to assess the Company’s ability to meet its contractual commitments and obligations over the next twelve months. There remains uncertainty given the unprecedented nature of the COVID-19 pandemic and the impact this may have on management’s assumptions used to develop these forecasts. Currently, management’s forecasts support the Company’s ability to meet all covenant compliance and its contractual obligations in the next twelve months such as payment of interest on the 5% convertible notes (refer to Note 11 and Note 17), payment of principal and interest on the Senior Facility (refer to Note 12 and Note 17), non-cancelable minimum purchase commitments for inventory (refer to Note 1 7 ), payment of the ABG finance liability (refer to Note 1 7 ), payment of the Company’s lease commitments (refer to Note 1 7 ) and payment of the Company’s Portugal construction commitments (refer to Note 1 7 ). Should there be additional constraints on access to capital under the at-the-market program, the Company can manage cash-outflows through reduced capital expenditures and managing the operational expenses of the business that pertain to future investments that are discretionary in nature. Accordingly, the Company has concluded it is probable it can implement plans that would effectively mitigate the conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern for the next twelve months. These financial statements do not include any adjustments to the carrying amount and classification of reported assets, liabilities, revenues or expenses that might be necessary should the Company not be successful with the aforementioned initiatives. Any such adjustments could be material. Change in comparative presentation The Company lost its emerging growth company status effective December 31, 2019 and therefore reported as a large accelerated filer in the Annual Financial Statements. As a result, the Company complies with new and revised accounting standards applicable to public companies. In the fourth quarter of 2019, the Company adopted the following accounting pronouncements issued by FASB: ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”); ASU 2016-02, Leases, codified as ASC 842 (“ASC 842”); ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU, codified as ASC 606 (“ASC 606”); and ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), as described in the Annual Financial Statements, with an effective date of January 1, 2019. The comparative three months ended March 31, 2019 included in the financial statements reflects the new and revised accounting standards and therefore does not mirror the March 31, 2019 interim period condensed consolidated financial statements previously filed. The impact to statements of net loss and comprehensive loss for the three months ended March 31, 2019 is as follows: Net loss Other comprehensive (loss) income Unadjusted $ (30,301 ) $ 933 Impact of adoption of accounting standards: ASU 2016-01 1,389 (1,389 ) ASC 842 (27 ) — ASU 2018-07 (430 ) — ASC 606 — — Adjusted $ (29,369 ) $ (456 ) The statement of net loss and comprehensive loss for the three months ended March 31, 2019 was reclassified to conform to the current period’s presentation. Cost of sales, which was formerly presented as a single line item, is now broken out between product costs and inventory valuation adjustments. Loss on disposal of property and equipment, formerly presented in other expenses (income) is now presented in general and administrative expenses.
Allowance for Credit Losses	Allowance for credit losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This guidance was subsequently amended by ASU 2018-19, Codification Improvements, ASU 2019-04, Codification Improvements, ASU 2019-05, Targeted Transition Relief, ASU 2019-10, Effective Dates, and ASU 2019-11, Codification Improvements. These ASUs are referred to collectively as the new guidance on current expected credit loss (“CECL”). As a result of the adoption of the new CECL guidance on January 1, 2020, the Company has changed its accounting policy for the allowance for credit losses, as it relates to accounts receivable and available-for-sale debt securities. The adoption of the CECL guidance did not have a material impact on the consolidated financial statements at January 1, 2020. Accounts receivable The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses. The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classes and the expected future loss. This assessment incorporates all available information relevant to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts. As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class. Available-for-sale debt securities The Company assesses its available-for-sale debt securities for impairment at each measurement date. When the fair value is less than the amortized cost, the Company assesses whether it intends to sell the security. When it is assessed that the Company will sell the security or the Company will be required to sell before recovery, the difference between the fair value and amortized cost is recorded as an impairment of assets in the statements of net loss and comprehensive loss. When the Company does not intend to sell and it is not more likely than not that the Company will be required to sell before recovery, the Company assesses whether a portion of the unrealized loss is a result of a credit loss. The Company recognizes the portion related to credit loss as credit loss expenses in general and administrative expenses within the statements of net loss and comprehensive loss and the portion of unrealized loss related to factors other than credit losses in other comprehensive loss. The Company determines the best estimate of the present value of cash flows expected to be collected from the available-for-sale debt securities on an individual basis based on past events, current conditions and forecasts relevant to the individual securities.
Disclosure Framework - Fair Value Measurement	Disclosure framework - fair value measurement In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) (“ASU 2018-13”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC Topic 820, (b) the policy for timing of transfers between levels, and (c) the valuation process used for Level 3 fair value measurements. ASU 2018-13 also adds, among other items, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The Company adopted ASU 2018-13 effective January 1, 2020 and such adoption did not have a material effect on its financial statements.
Warrants	Warrants In March 2020, the Company closed on a registered offering including Class 2 common stock, warrants and pre-funded warrants (refer to Note 13). As a result, the Company has adopted an accounting policy for warrants. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company's warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each balance sheet date until settlement and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of net loss and comprehensive loss. Transaction costs allocated to warrants that are presented as a liability are expensed immediately within other expenses (income) in the statements of net loss and comprehensive loss.
Use of Estimates and Significant Estimates	Use of estimates and significant estimates Allowance for credit losses – The Company’s projections of expected credit losses are inherently uncertain, and as a result the Company cannot predict with certainty the amount of such losses. Changes in economic conditions, the risk characteristics and composition of the portfolio, bankruptcy laws, and other factors could impact the actual and projected expected credit losses and the related allowance for credit losses. Actual losses may vary from current estimates. Due to potential COVID-19 disruptions in the marketplace it is possible the Company may experience unforeseen and greater credit losses than anticipated or experienced historically. Warrant liability – The Company estimates the fair value of the warrant liability using a Monte Carlo pricing model. The Company is required to make assumptions and estimates in determining an appropriate risk-free interest rate, volatility, term, dividend yield and discount due to exercise restrictions and fair value of common stock.
Net Loss Per Share	Net loss per share Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of warrants, stock options, restricted stock units (“RSUs”) and restricted stock awards. In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. As of March 31, 2020, there were 21,266,707 common share equivalents with potential dilutive impact (March 31, 2019 – 8,266,509 ). Since the Company is in a net loss for all periods presented in these financial statements, there is no difference between the Company’s basic and diluted net loss per share for the periods p resented.
New Accounting Pronouncements Not Yet Adopted	New accounting pronouncements not yet adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU. In January 2020, the FASB issued ASU 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Impact to Statements of Net Loss and Comprehensive Loss	The impact to statements of net loss and comprehensive loss for the three months ended March 31, 2019 is as follows: Net loss Other comprehensive (loss) income Unadjusted $ (30,301 ) $ 933 Impact of adoption of accounting standards: ASU 2016-01 1,389 (1,389 ) ASC 842 (27 ) — ASU 2018-07 (430 ) — ASC 606 — — Adjusted $ (29,369 ) $ (456 )

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory is comprised of the following items: March 31, 2020 December 31, 2019 Raw materials $ 20,336 $ 15,926 Work-in-process 62,584 53,973 Finished goods 12,666 17,962 Total $ 95,586 $ 87,861
Schedule of Inventory Valuation Adjustments Included in Cost of Sales	Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following: Three months ended March 31, 2020 2019 Raw materials $ 85 $ — Work-in-process 2,853 324 Finished goods 1,106 — Total $ 4,044 $ 324

Prepayments and Other Current_2

Prepayments and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Schedule of Prepayments and Other Current Assets	Prepayments and other current assets are comprised of the following items: March 31, 2020 December 31, 2019 Deposits $ 20,079 $ 25,490 Prepayments 4,376 5,847 Taxes receivable 6,611 6,165 ABG finance receivable - current — 671 Total $ 31,066 $ 38,173

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Long-term Investments	Long-term investments are comprised of the following items: March 31, 2020 December 31, 2019 Equity investments at fair value $ 1,838 $ 4,183 Equity investments under measurement alternative 14,232 14,954 Debt securities classified under available-for-sale method 5,180 5,047 Total other investments $ 21,250 $ 24,184
Summary of Ownership Interests in Equity Method Investments	The Company’s ownership interests in its equity method investments as of March 31, 2020 and December 31, 2019 and loss from equity method investments for the three months ended March 31, 2020 were as follows: Approximate Carrying value Gain (loss) from equity method investments for the three months ended ownership % March 31, 2020 March 31, 2020 Investment in Fluent 50% $ 5,419 $ (1,819 ) Investment in Cannfections 50% 3,408 71 Total equity method investments $ 8,827 $ (1,748 ) Approximate Carrying value Gain (loss) from equity method investments for the three months ended ownership % December 31, 2019 March 31, 2019 Investment in Fluent 50% $ 7,836 $ — Investment in Cannfections 50% 3,612 — Total equity method investments $ 11,448 $ —
Summary of Financial Information for Equity Method Investments	Summary financial information for the equity method investments on an aggregate basis was as follows: March 31, 2020 December 31, 2019 Current assets $ 11,538 $ 13,942 Noncurrent assets $ 4,525 $ 4,987 Current liabilities $ 3,472 $ 1,561 Noncurrent liabilities $ — $ — Three months ended March 31, 2020 2019 Revenue $ 1,392 $ — Gross profit $ 583 $ — Net loss $ (3,496 ) $ —

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	3 Months Ended
	Mar. 31, 2020
Allowance For Credit Loss [Abstract]
Schedule of Allowance for Credit Losses	The following table provides activity in the allowance for credit losses for the three months ended March 31, 2020: Allowance for credit losses, January 1, 2020 $ 615 Provision for expected credit losses (1) 46 Write-offs charged against allowance (19 ) Recoveries of amounts previously written off — Foreign currency translation adjustment (47 ) Allowance for credit losses, March 31, 2020 $ 595 Accounts receivable balance before allowance for credit losses and provision for sales returns, March 31, 2020 $ 40,057 (1) The provision for expected credit losses is recorded in general and administrative expenses
Schedule of Fair Value and Unrealized Loss of Investment	The following table provides the fair value and unrealized loss of the investment at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Fair value $ 900 $ 945 Unrealized loss $ 376 $ 302

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net consists of the following: March 31, 2020 December 31, 2019 Land $ 6,117 $ 6,417 Buildings and leasehold improvements 109,413 109,172 Laboratory and manufacturing equipment 31,508 31,173 Office and computer equipment 2,514 2,659 Right-of-use ("ROU") assets under finance lease 13,628 14,753 Construction-in-process, not yet available for use 42,590 37,160 205,770 201,334 Less: accumulated depreciation (18,800 ) (17,117 ) Total $ 186,970 $ 184,217

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill Disclosure [Abstract]
Schedule of Change in Carrying Amount of Goodwill	The following table shows the change in carrying amount of goodwill: Hemp Cannabis Total Balance as of December 31, 2019 $ 133,314 $ 29,937 $ 163,251 Foreign currency translation adjustment (10,097 ) (2,284 ) (12,381 ) Balance as of March 31, 2020 $ 123,217 $ 27,653 $ 150,870

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Intangible Assets Net Excluding Goodwill [Abstract]
Schedule of Intangible Assets	Intangible assets are comprised of the following items: March 31, December 31, 2020 2019 Cost Accumulated Amortization Impairment Net Cost Accumulated Amortization Impairment Net Definite-lived intangible assets: Patent $ 670 $ 130 $ — $ 540 $ 716 $ 99 $ — $ 617 Customer relationships 125,581 8,565 — 117,016 135,953 7,132 — 128,821 Developed technology 6,535 708 — 5,827 7,074 590 — 6,484 Websites 4,927 3,319 — 1,608 5,157 3,331 — 1,826 Trademarks and licenses 9,014 1,212 6,063 1,739 9,135 925 — 8,210 Total 146,727 13,934 6,063 126,730 158,035 12,077 — 145,958 Indefinite-lived intangible assets: Cultivation license 9,873 — — 9,873 10,689 — — 10,689 Alef license — — — — 4,086 — 4,086 — Trademarks 51,289 — — 51,289 55,416 — — 55,416 Rights under ABG Profit Participation Arrangement 16,765 — 16,765 — 119,366 — 102,601 16,765 Total 77,927 — 16,765 61,162 189,557 — 106,687 82,870 Total intangible assets $ 224,654 $ 13,934 $ 22,828 $ 187,892 $ 347,592 $ 12,077 $ 106,687 $ 228,828
Schedule of Future Amortization Expenses for Intangible Assets	Amortization expenses for intangibles was $1,857 for the three months ended March 31, 2020 (2019 - $1,558). Expected future amortization expenses for intangible assets as at March 31, 2020 are as follows: Year ending December 31, Amortization 2020 (remaining nine months) $ 7,392 2021 9,557 2022 9,033 2023 8,662 2024 8,658 Thereafter 83,428 Total $ 126,730

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following items: March 31, 2020 December 31, 2019 Accrued payroll and employment related withholding taxes $ 10,986 $ 24,765 Other accrued expenses and current liabilities 22,297 17,032 Accrued interest on Senior Facility 448 — Accrued interest on convertible notes 11,875 5,938 ABG finance liability - current 875 1,500 Accrued legal and professional fees 158 1,174 Contingent consideration for acquisitions 393 420 Total accrued expenses and other current liabilities $ 47,032 $ 50,829

Convertible Notes (Tables)

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Components of Net Carrying Amount of Convertible Notes	The following table sets forth the net carrying amount of the convertible notes: March 31, 2020 December 31, 2019 5.00% Convertible Notes $ 475,000 $ 475,000 Unamortized discount (32,210 ) (34,219 ) Unamortized transaction costs (9,983 ) (10,571 ) Net carrying amount $ 432,807 $ 430,210
Schedule of Interest Expenses	The following table sets forth total interest expense recognized related to the convertible notes: Three months ended March 31, 2020 2019 Contractual coupon interest $ 5,938 $ 5,938 Amortization of discount 2,009 1,892 Amortization of transaction costs 588 609 Total $ 8,535 $ 8,439

Senior Facility (Tables)

Senior Facility (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Instrument [Line Items]
Schedule of Components of Net Carrying Amount of Senior Facility	The following table sets forth the net carrying amount of the Senior Facility: March 31, 2020 Senior Facility $ 46,841 Unamortized transaction costs (3,012 ) Net carrying amount $ 43,829 Less: current portion of Senior Facility (4,723 ) Total noncurrent portion of Senior Facility $ 39,106
Schedule of Interest Expenses	The following table sets forth total interest expense recognized related to the convertible notes: Three months ended March 31, 2020 2019 Contractual coupon interest $ 5,938 $ 5,938 Amortization of discount 2,009 1,892 Amortization of transaction costs 588 609 Total $ 8,535 $ 8,439
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Schedule of Interest Expenses	The following table sets forth total interest expense recognized related to the Senior Facility: Three months ended March 31, 2020 Contractual interest at Canadian prime plus 8.05% $ 480 Amortization of transaction costs 131 Total $ 611

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Class Of Stock [Line Items]
Schedule of Pre-funded Warrants and Warrants Outstanding	Pre-funded warrants and warrants outstanding at March 31, 2020, and related activity for the three months ended March 31, 2020 is as follows (reflects the number of Class 2 common stock as if the warrants were converted to Class 2 common stock): Description Classification Exercise price Expiration date Balance December 31, 2019 Issued Exercised Balance March 31, 2020 Pre-Funded Warrants Liability $ 0.0001 March 17, 2025 — 11,750,000 (11,750,000 ) — Warrants Liability $ 5.95 March 17, 2025 — 19,000,000 — 19,000,000 Total — 30,750,000 (11,750,000 ) 19,000,000
Schedule of Estimated Fair Value of Warrant Liability	Quantitative information about Level 3 fair value measurements Fair value at March 31, 2020 Valuation technique Unobservable input Range (weighted average) Discount rate 16.5% Debt securities classified as available-for-sale $ 4,541 Discounted cash flow Probability of conversion/ prepayment nil Probability of default nil Acquisition-related contingent consideration $ (393 ) Discounted cash flow Discount rate 15% Assumed likelihood of milestone payments 50% - 90% Volatility 118% Warrant liability $ (92,339 ) Monte Carlo Restriction 17% Expected life 0.5 years to 5.5 years (2.5 years)
Warrant [Member]
Class Of Stock [Line Items]
Schedule of Estimated Fair Value of Warrant Liability	The Company estimated the fair value of the Warrant liability at March 31, 2020 using the Monte Carlo pricing model (Level 3) with the following weighted-average assumptions: Risk-free interest rate 0.94 % Expected volatility 118 % Expected term 5.5 years Expected dividend yield 0 % Strike price $ 5.95 Fair value of common stock $ 6.88 Discount due to exercise restrictions 17 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Summary of Capital Stock	The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of March 31, 2020. The liquidation and dividend rights are identical among Class 1 common stock and Class 2 common stock, and all classes of common stock share equally in the Company’s earnings and losses. Par Value Authorized Voting Rights Class 1 common stock $ 0.0001 250,000,000 10 votes for each share Class 2 common stock $ 0.0001 500,000,000 1 vote for each share Preferred stock $ 0.0001 10,000,000 N/A

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Original Stock Option Plan [Member]
Schedule of Stock Option Activity	Stock option activity under the Original Plan is as follows: Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 3,014,004 $ 3.04 5.8 $ 44,108 Exercised (217,982 ) 0.27 Forfeited (36,612 ) 4.21 Cancelled (3,197 ) 4.44 Balance March 31, 2020 2,756,213 $ 3.20 5.6 $ 39,680 Vested and expected to vest, March 31, 2020 2,742,644 $ 3.18 5.6 $ 39,525 Vested and exercisable, March 31, 2020 2,563,446 $ 3.00 5.4 $ 37,319
2018 Equity Incentive Plan [Member] | Time-based Stock Options [Member]
Schedule of Stock Option Activity	Time-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 5,307,130 $ 14.04 8.4 $ 44,297 Granted — — Exercised (169,817 ) 7.76 Forfeited (95,340 ) 17.04 Cancelled (5,596 ) 62.32 Balance March 31, 2020 5,036,377 $ 14.14 8.1 $ — Vested and expected to vest, March 31, 2020 4,863,171 $ 13.93 8.1 $ — Vested and exercisable, March 31, 2020 2,707,014 $ 12.29 8.1 $ —
2018 Equity Incentive Plan [Member] | Performance-based Stock Options [Member]
Schedule of Stock Option Activity	Performance-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 520,000 $ 7.76 8.4 $ 4,872 Granted — — — Exercised — — Forfeited — — — Cancelled — — — Balance March 31, 2020 520,000 $ 7.76 8.1 $ — Vested and expected to vest, March 31, 2020 520,000 $ 7.76 8.1 $ — Vested and exercisable, March 31, 2020 520,000 $ 7.76 8.1 $ —
2018 Equity Incentive Plan [Member] | Time-based RSU [Member]
Schedule of RSU Activity	Time-based RSU activity Time-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 1,423,392 $ 42.05 Granted 752,283 11.20 Vested (154,642 ) 55.92 Forfeited (186,454 ) 45.27 Non-vested March 31, 2020 1,834,579 $ 27.90
2018 Equity Incentive Plan [Member] | Performance-based RSUs [Member]
Schedule of RSU Activity	Performance-based RSUs activity Performance-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 265,625 $ 7.76 Vested (53,125 ) 7.76 Non-vested March 31, 2020 212,500 $ 7.76

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	The components of AOCI, net of tax, were as follows: Foreign Currency Translation Adjustments Unrealized (loss) gain on available-for-sale debt securities Total Balance as at December 31, 2019 $ 10,021 $ (302 ) $ 9,719 Other comprehensive loss: Change in foreign currency translation (16,633 ) — (16,633 ) Change in unrealized losses on available-for-sale debt securities — (74 ) (74 ) Balance as at March 31, 2020 $ (6,612 ) $ (376 ) $ (6,988 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Maturities of Lease Liabilities	Maturities of lease liabilities: Year ending December 31, Operating Leases Finance Leases 2020 (remaining nine months) $ 2,799 $ 614 2021 3,025 798 2022 2,944 5,686 2023 2,844 11,545 2024 2,443 — Thereafter 7,801 — Total lease payments $ 21,856 $ 18,643 Imputed interest 3,161 5,430 Obligations recognized $ 18,695 $ 13,213
Schedule of Future Non-cancellable Minimum Purchase Commitments	The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of March 31, 2020: Total 2020 (remaining nine months) 2021 2022 2023 2024 Thereafter Purchase commitments $ 113,047 $ 111,445 $ 1,530 $ 36 $ 36 $ — $ — Total $ 113,047 $ 111,445 $ 1,530 $ 36 $ 36 $ — $ —
Schedule of Other Commitments Maturities	Total 2020 (remaining nine months) 2021 2022 2023 2024 Thereafter ABG finance liability $ 8,000 $ 500 $ 1,500 $ 1,500 $ 1,500 $ 1,500 $ 1,500 Convertible notes, principal and interest 570,000 23,750 23,750 23,750 498,750 — — Senior Facility, principal and interest 55,765 7,918 9,001 38,846 — — — Portugal construction commitments 17,423 17,423 — — — — — Total $ 651,188 $ 49,591 $ 34,251 $ 64,096 $ 500,250 $ 1,500 $ 1,500

General and Administrative Ex_2

General and Administrative Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
General And Administrative Expense [Abstract]
Schedule of General and Administrative Expenses	General and administrative expenses are comprised of the following items: Three months ended March 31, 2020 2019 Salaries $ 7,296 $ 6,411 Professional fees 4,521 2,457 Travel expenses 963 721 Other expenses 4,493 2,698 Credit loss expenses 46 536 Loss on disposal of property and equipment 457 111 Total $ 17,776 $ 12,934

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Three months ended March 31, 2020 2019 Cash paid for interest $ 704 $ 73 Non-cash financing activities Shares issued for employee compensation $ — $ 649 Non-cash investing Acquisition of Manitoba Harvest $ — $ 195,407 Acquisition of Natura $ — $ 38,980 Investment in ABG Profit Participation Arrangement, net of receivable $ — $ 94,805
Summary of Supplemental Cash Flow Information Related to Leases	Three months ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 854 $ 247 Operating cash flows from finance leases $ 142 $ — Financing cash flows from finance leases $ 105 $ — Non-cash additions to Right-of-use assets and lease liabilities Operating leases $ 423 $ 3,431 Finance leases $ — $ —

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring and Non-recurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total March 31, 2020 Investments Equity investments measured at fair value $ 1,838 $ — $ — $ 1,838 Debt securities classified as available-for-sale 639 — 4,541 5,180 Acquisition-related contingent consideration — — (393 ) (393 ) Warrant liability — — (92,339 ) (92,339 ) Total recurring fair value measurements $ 2,477 $ — $ (88,191 ) $ (85,714 ) Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2019 Investments Equity investments measured at fair value $ 4,183 $ — $ — $ 4,183 Debt securities classified as available-for-sale 727 — 4,320 5,047 Acquisition-related contingent consideration — — (420 ) (420 ) Total recurring fair value measurements $ 4,910 $ — $ 3,900 $ 8,810
Schedule of Opening Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis are Reconciled to Closing Balances	The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows: Debt securities classified as available-for- sale Acquisition- related contingent consideration Warrant liability Opening balance as at December 31, 2019 $ 4,320 $ (420 ) $ — Additions and settlements Additions — — (69,414 ) Exercise — — 49,053 Total gains or losses for the period: — — — Included in net loss — — — Interest expenses, net 221 — — Change in fair value of warrant liability — — (71,978 ) Foreign currency translation loss, net — 27 — Closing balance as at March 31, 2020 $ 4,541 $ (393 ) $ (92,339 )
Schedule of Estimated Fair Value of Warrant Liability	Quantitative information about Level 3 fair value measurements Fair value at March 31, 2020 Valuation technique Unobservable input Range (weighted average) Discount rate 16.5% Debt securities classified as available-for-sale $ 4,541 Discounted cash flow Probability of conversion/ prepayment nil Probability of default nil Acquisition-related contingent consideration $ (393 ) Discounted cash flow Discount rate 15% Assumed likelihood of milestone payments 50% - 90% Volatility 118% Warrant liability $ (92,339 ) Monte Carlo Restriction 17% Expected life 0.5 years to 5.5 years (2.5 years)

Business Segment Information (T

Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Summary of Revenue and Gross Profit	The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and gross profit as the measure of segment profit or loss. The accounting policies of each segment are the same as those set out under the summary of significant accounting policies in Note 1. There are no intersegment sales or transfers. The comparative three months ended March 31, 2019 have been recast to reflect to the current segment structure. Three months ended March 31, 2020 2019 Revenue Gross profit Revenue Gross profit Cannabis $ 30,776 $ 2,926 $ 17,456 $ 3,621 Hemp $ 21,326 $ 7,944 $ 5,582 $ 1,764 Total $ 52,102 $ 10,870 $ 23,038 $ 5,385 No asset information is provided for the segments because the Company’s chief operating decision maker does not review this information by segment on a regular basis. Total revenue and gross profit for the reportable segments is equal to the Company’s consolidated revenue and gross profit. Three months ended March 31, 2020 2019 Gross profit for the segments $ 10,870 $ 5,385 General and administrative expenses 17,776 12,934 Sales and marketing expenses 17,876 7,821 Research and development expenses 1,258 1,048 Depreciation and amortization expenses 3,591 1,865 Stock-based compensation expense 7,677 5,736 Impairment of assets 29,839 — Acquisition-related expenses, net 2,355 4,424 Loss from equity method investments 1,748 — Foreign exchange loss, net 28,069 179 Change in fair value of warrant liability 71,978 — Interest expenses, net 9,146 8,744 Finance income from ABG — (135 ) Other expense (income), net 4,651 (3,845 ) Loss before income taxes $ (185,094 ) $ (33,386 )
Summary of Revenue Attributed to a Geographic Region Based on the Location of the Customer	Revenue attributed to geographic region based on the location of the customer was as follows: Three months ended March 31, 2020 2019 Canada $ 29,488 $ 17,002 United States 16,530 4,225 Other countries 6,084 1,811 Total $ 52,102 $ 23,038
Summary of Long-lived Assets Consisting of Property and Equipment, Net of Accumulated Depreciation, Attributed to Geographic Regions Based on their Physical Location	Long-lived assets consisting of property and equipment, net of accumulated depreciation, attributed to geographic regions based on their physical location were as follows: March 31, 2020 December 31, 2019 Canada $ 131,915 $ 144,065 Portugal 50,069 36,908 United States 4,824 3,171 Other countries 162 73 Total $ 186,970 $ 184,217

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Thousands	Mar. 17, 2020USD ($)$ / shares	Mar. 31, 2020USD ($)$ / shares	Mar. 31, 2019USD ($)	Feb. 28, 2020USD ($)	Feb. 28, 2020CAD ($)	Dec. 31, 2019USD ($)
Summary Of Significant Accounting Policies [Line Items]
Net loss		$ (184,123,000)	$ (29,369,000)
Net cash used in operating activities		(54,031,000)	(24,841,000)
Net cash outflows		77,199,000	$ (193,050,000)
Working capital		167,595,000				$ 166,600,000
Increase in cash due to working capital adjustments		995,000
Proceeds from registered equity offering, gross	$ 85,289,000
Proceeds from registered equity offering, net	$ 90,439,000	$ 85,465,000
Convertible Senior Notes Due 2023 [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument interest rate		5.00%
Senior Secured Term Loan Facility [Member] | High Park Holdings Ltd. [Member]
Summary Of Significant Accounting Policies [Line Items]
Amount withdrawable on election		$ 9,900,000		$ 9,900,000	$ 13,300
Class 2 Common Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional debt financing for managing operation				$ 59,600,000
Proceeds from registered equity offering, gross		27,579,000
Maximum allowed aggregate gross proceeds from share issuance under ATM program		$ 20,000,000
Warrant exercise price | $ / shares	$ 5.95	$ 5.95
Maximum amount of share issuance allowed per quarter		$ 6,000,000
Class 2 Common Stock [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Warrant issue, price per share threshold limit | $ / shares		$ 11.90

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Impact to Statements of Net Loss and Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net loss	$ (184,123)	$ (29,369)
Other comprehensive (loss) income	$ (16,707)	(456)
Unadjusted [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net loss		(30,301)
Other comprehensive (loss) income		933
Impact of Adoption [Member] | ASU 2016-01 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net loss		1,389
Other comprehensive (loss) income		(1,389)
Impact of Adoption [Member] | ASC 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net loss		(27)
Impact of Adoption [Member] | ASU 2018-07 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net loss		$ (430)

ABG Profit Participation Arra_2

ABG Profit Participation Arrangement - Additional Information (Detail) - A And R Profit Participation Agreement [Member] - USD ($)	Jan. 24, 2020	Jan. 31, 2020
Class Of Stock [Line Items]
Finance receivables write-offs through impairment of assets		$ 7,011,000
Finance receivable write-off through accumulated deficit		$ 28,900,000
ABG Intermediate Holdings Two LLC [Member]
Class Of Stock [Line Items]
Minimum participation rights with respect to each contract year	$ 10,000,000
Class 2 Common Stock [Member] | ABG Intermediate Holdings Two LLC [Member]
Class Of Stock [Line Items]
Obligation to pay the additional consideration	$ (83,333,000)
Minimum [Member] | ABG Intermediate Holdings Two LLC [Member]
Class Of Stock [Line Items]
Percentage of participation rights	49.00%

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 20,336	$ 15,926
Work-in-process	62,584	53,973
Finished goods	12,666	17,962
Total Inventory	$ 95,586	$ 87,861

Inventory - Schedule of Inven_2

Inventory - Schedule of Inventory Valuation Adjustments Included in Cost of Sales (Detail) - Inventory Valuation and Obsolescence [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Inventory [Line Items]
Inventory valuation adjustments	$ 4,044	$ 324
Raw Materials [Member]
Inventory [Line Items]
Inventory valuation adjustments	85
Work In Process [Member]
Inventory [Line Items]
Inventory valuation adjustments	2,853	$ 324
Finished Goods [Member]
Inventory [Line Items]
Inventory valuation adjustments	$ 1,106

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cannabis [Member]
Inventory [Line Items]
Inventory write-downs	$ 3,247	$ 324
Hemp [Member]
Inventory [Line Items]
Inventory write-downs	$ 797	$ 0

Prepayments and Other Current_3

Prepayments and Other Current Assets - Schedule of Prepayments and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Deposits	$ 20,079	$ 25,490
Prepayments	4,376	5,847
Taxes receivable	6,611	6,165
ABG finance receivable - current		671
Total	$ 31,066	$ 38,173

Investments - Summary of Long-t

Investments - Summary of Long-term Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Equity investments at fair value	$ 1,838	$ 4,183
Equity investments under measurement alternative	14,232	14,954
Debt securities classified under available-for-sale method	5,180	5,047
Total other investments	$ 21,250	$ 24,184

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Unrealized gain (losses) on equity Investments	$ (1,534,000)	$ 1,396,000
Impairments or adjustments equity investments under measurement alternative	0	0
Credit loss expenses	46,000	536,000
Investment in joint venture under the equity method	8,827,000		$ 11,448,000
Fluent [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	5,419,000		7,836,000
Fluent [Member] | Joint Venture [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	0	0
Total fees charged	1,880,000	0
Fluent [Member] | Joint Venture [Member] | Accounts Receivable [Member]
Schedule Of Available For Sale Securities [Line Items]
Total fees charged	1,022,000		388,000
Cannfections [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	3,408,000		3,612,000
Cannfections [Member] | Joint Venture [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	0	0
Investment in Equities [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, allowance for credit loss	0		0
Credit loss expenses	0	$ 0
Long-term Investments [Member] | Investment in Equities [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, Gross unrealized losses	$ 376,000		$ 302,000
Convertible Debt Instrument [Member]
Schedule Of Available For Sale Securities [Line Items]
Convertible debt instruments contractual maturity	2022

Investments - Summary of Owners

Investments - Summary of Ownership Interests in Equity Method Investments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Carrying value	$ 8,827	$ 11,448
Gain (loss) from equity method investments	$ (1,748)
Fluent [Member]
Schedule Of Equity Method Investments [Line Items]
Approximate ownership %	50.00%	50.00%
Carrying value	$ 5,419	$ 7,836
Gain (loss) from equity method investments	$ (1,819)
Cannfections [Member]
Schedule Of Equity Method Investments [Line Items]
Approximate ownership %	50.00%	50.00%
Carrying value	$ 3,408	$ 3,612
Gain (loss) from equity method investments	$ 71

Investments - Summary of Financ

Investments - Summary of Financial Information for Equity Method Investments (Detail) - Equity Method Investments [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 11,538	$ 13,942
Noncurrent assets	4,525	4,987
Current liabilities	3,472	$ 1,561
Revenue	1,392
Gross profit	583
Net loss	$ (3,496)

Allowance for Credit Losses - S

Allowance for Credit Losses - Schedule of Allowance for Credit Losses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Allowance For Credit Loss [Abstract]
Allowance for credit losses, January 1, 2020	$ 615
Credit loss expenses	46	$ 536
Write-offs charged against allowance	(19)
Foreign currency translation adjustment	(47)
Allowance for credit losses, March 31, 2020	595
Accounts receivable balance before allowance for credit losses and provision for sales returns, March 31, 2020	$ 40,057

Allowance for Credit Losses - A

Allowance for Credit Losses - Additional Information (Detail)	Mar. 31, 2020InvestmentHolding
Allowance For Credit Loss [Abstract]
Number of available for sale debt securities	2
Number of available for sale securities in unrealized loss position	1

Allowance for Credit Losses -_2

Allowance for Credit Losses - Schedule of Fair Value and Unrealized Loss of Investment (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Fair value	$ 900	$ 945
Unrealized loss	$ 376	$ 302

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 205,770	$ 201,334
Less: accumulated depreciation	(18,800)	(17,117)
Total	186,970	184,217
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,117	6,417
Buildings and Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	109,413	109,172
Laboratory and Manufacturing Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	31,508	31,173
Office and Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,514	2,659
Right-of-Use ("ROU") Assets Under Finance Lease [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	13,628	14,753
Construction-in-Process, Not Yet Available for Use [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 42,590	$ 37,160

Goodwill - Schedule of Change i

Goodwill - Schedule of Change in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill [Line Items]
Balance as of December 31, 2019	$ 163,251
Foreign currency translation adjustment	(12,381)
Balance as of March 31, 2020	150,870
Hemp [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	133,314
Foreign currency translation adjustment	(10,097)
Balance as of March 31, 2020	123,217
Cannabis [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	29,937
Foreign currency translation adjustment	(2,284)
Balance as of March 31, 2020	$ 27,653

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Goodwill	$ 150,870,000	$ 163,251,000
Goodwill, impaired, facts and circumstances leading to impairment	A relatively small change in the underlying assumptions, including a 1% change in the weighted average cost of capital, continued lack of clarity from the Food and Drug Administration regarding approval of CBD or the financial performance of the reporting unit in future years may cause a change in the results of the impairment assessment in future periods and, as such, could result in an impairment of goodwill.
Hemp Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	$ 123,217,000
Reporting unit, percentage of fair value in excess of carrying amount	26.00%
Reporting unit, amount of fair value in excess of carrying amount	$ 76,998,000
Goodwill impairment loss	$ 0
Hemp Reporting Unit [Member] | Minimum [Member]
Goodwill [Line Items]
Weighted average cost of capital discount rate	10.00%
Hemp Reporting Unit [Member] | Minimum [Member] | Revenue and Expense Growth Assumptions
Goodwill [Line Items]
Reporting unit, percentage of fair value in excess of carrying amount	9.00%
Hemp Reporting Unit [Member] | Maximum [Member]
Goodwill [Line Items]
Weighted average cost of capital discount rate	12.00%
Hemp Reporting Unit [Member] | Maximum [Member] | Revenue and Expense Growth Assumptions
Goodwill [Line Items]
Reporting unit, percentage of fair value in excess of carrying amount	38.00%

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	$ 146,727	$ 158,035
Definite-lived intangible asset, Accumulated Amortization	13,934	12,077
Definite-lived intangible asset, Impairment	6,063
Definite-lived intangible asset, Net	126,730	145,958
Indefinite-lived intangible asset, Cost	77,927	189,557
Indefinite-lived intangible asset, Impairment	16,765	106,687
Indefinite-lived intangible asset, Net	61,162	82,870
Total intangible asset, Cost	224,654	347,592
Total intangible asset, Impairment	22,828	106,687
Total intangible asset, Net	187,892	228,828
Patents [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	670	716
Definite-lived intangible asset, Accumulated Amortization	130	99
Definite-lived intangible asset, Net	540	617
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	125,581	135,953
Definite-lived intangible asset, Accumulated Amortization	8,565	7,132
Definite-lived intangible asset, Net	117,016	128,821
Developed Technology [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	6,535	7,074
Definite-lived intangible asset, Accumulated Amortization	708	590
Definite-lived intangible asset, Net	5,827	6,484
Websites [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	4,927	5,157
Definite-lived intangible asset, Accumulated Amortization	3,319	3,331
Definite-lived intangible asset, Net	1,608	1,826
Trademarks and Licenses [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	9,014	9,135
Definite-lived intangible asset, Accumulated Amortization	1,212	925
Definite-lived intangible asset, Impairment	6,063
Definite-lived intangible asset, Net	1,739	8,210
Cultivation License [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost	9,873	10,689
Indefinite-lived intangible asset, Net	9,873	10,689
Alef License [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost		4,086
Indefinite-lived intangible asset, Impairment		4,086
Trademarks [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost	51,289	55,416
Indefinite-lived intangible asset, Net	51,289	55,416
Rights under ABG Profit Participation Arrangement [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost	16,765	119,366
Indefinite-lived intangible asset, Impairment	$ 16,765	102,601
Indefinite-lived intangible asset, Net		$ 16,765

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Intangible assets available for use	$ 126,730,000		$ 145,958,000
Non-cash impairment charge of intangible assets	6,063,000
Non-cash impairment charge of intangible assets	16,765,000		106,687,000
Amortization expenses for intangible assets	1,857,000	$ 1,558,000
Intangible Assets Not Yet Available For Use [Member]
Finite Lived Intangible Assets [Line Items]
Intangible assets available for use	0		0
ABG Prince Agreement [Member]
Finite Lived Intangible Assets [Line Items]
Non-cash impairment charge of intangible assets	6,063,000
ABG Profit Participation Arrangement [Member]
Finite Lived Intangible Assets [Line Items]
Non-cash impairment charge of intangible assets	$ 16,765,000		$ 102,601,000

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Future Amortization Expenses for Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2020 (remaining nine months)	$ 7,392
2021	9,557
2022	9,033
2023	8,662
2024	8,658
Thereafter	83,428
Definite-lived intangible asset, Net	$ 126,730	$ 145,958

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Accrued payroll and employment related withholding taxes	$ 10,986	$ 24,765
Other accrued expenses and current liabilities	22,297	17,032
Accrued interest on Senior Facility	448
Accrued interest on convertible notes	11,875	5,938
Accrued legal and professional fees	158	1,174
Contingent consideration for acquisitions	393	420
Total accrued expenses and other current liabilities	47,032	50,829
ABG [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
ABG finance liability - current	$ 875	$ 1,500

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	$ 1,861
Payments to employees	1,523
Amount included in accrued payroll	338
Cannabis Reportable Segment [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	1,424
Hemp Reportable Segment [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	437
General and Administrative Expense [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	1,580
Cost of Sales [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	$ 281

Convertible Notes - Additional

Convertible Notes - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Convertible Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 475,000	$ 475,000

Convertible Notes - Schedule of

Convertible Notes - Schedule of Components of Net Carrying Amount of Convertible Notes (Detail) - Convertible Senior Notes Due 2023 [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
5.00% Convertible Notes	$ 475,000	$ 475,000
Unamortized discount	(32,210)	(34,219)
Unamortized transaction costs	(9,983)	(10,571)
Net carrying amount	$ 432,807	$ 430,210

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Interest Expense Schedule of Interest Expense Related to Convertible Notes (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Amortization of discount	$ 2,597	$ 2,501
Convertible Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Contractual coupon interest	5,938	5,938
Amortization of discount	2,009	1,892
Amortization of transaction costs	588	609
Total	$ 8,535	$ 8,439

Senior Facility - Additional In

Senior Facility - Additional Information (Detail)	Feb. 28, 2020USD ($)	Feb. 28, 2020CAD ($)	Mar. 31, 2020USD ($)	Feb. 28, 2020CAD ($)
Line of Credit Facility [Line Items]
Canadian prime rate			8.05%
Senior Secured Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Canadian prime rate			8.05%
Senior Secured Term Loan Facility [Member] | High Park Holdings Ltd. [Member]
Line of Credit Facility [Line Items]
Maximum aggregate principal amount	$ 59,600,000			$ 79,800,000
Amount drawn at closing	49,700,000			66,500,000
Amount withdrawable on election	$ 9,900,000		$ 9,900,000	13,300,000
Canadian prime rate	8.05%	8.05%
Principal repayment amount	$ 394,000	$ 554,000
Aggregate repayment amount	$ 37,788,000			53,200,000
Frequency of repayment	monthly	monthly
Frequency of payment and payment terms	Interest is due monthly throughout the term. The Closing Date Draw principal repayments of $394 (C$554) are due monthly which will result in an aggregate balance of $37,788 (C$53,200) due at February 28, 2022. The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice.	Interest is due monthly throughout the term. The Closing Date Draw principal repayments of $394 (C$554) are due monthly which will result in an aggregate balance of $37,788 (C$53,200) due at February 28, 2022. The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice.
Transaction fees incurred	$ 3,306,000			4,425,000
Transaction fees estimated on additional draw	567,000			798,000
Minimum unrestricted cash threshold for capital expenditures and investments	$ 28,412,000			$ 40,000,000

Senior Facility - Schedule of C

Senior Facility - Schedule of Components of Net Carrying Amount of Senior Facility (Detail) - Senior Secured Term Loan Facility [Member] $ in Thousands	Mar. 31, 2020USD ($)
Debt Instrument [Line Items]
Debt instrument, face amount	$ 46,841
Unamortized transaction costs	(3,012)
Net carrying amount	43,829
Less: current portion of Senior Facility	(4,723)
Total noncurrent portion of Senior Facility	$ 39,106

Senior Facility - Schedule of I

Senior Facility - Schedule of Interest Expenses Recognized Related to Senior Facility (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Amortization of discount on convertible notes	$ 2,597	$ 2,501
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Contractual interest at Canadian prime plus 8.05%	480
Amortization of discount on convertible notes	131
Total	$ 611

Senior Facility - Schedule of_2

Senior Facility - Schedule of Interest Expenses Recognized Related to Senior Facility (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2020
Debt Instrument [Line Items]
Canadian prime rate	8.05%
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Canadian prime rate	8.05%

Registered Offering and Warrant

Registered Offering and Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 17, 2020	Mar. 31, 2020
Class Of Stock [Line Items]
Warrants to purchase		19,000,000
Shares issued for common stock at-the-market, net of issuance costs	$ 90,439	$ 27,027
Issuance costs incurred on registered offering	$ 5,150
Daily cash penalty	1.00%
Other Expense (Income) [Member]
Class Of Stock [Line Items]
Issuance costs incurred on registered offering	$ 3,953
Pre funded Warrants [Member]
Class Of Stock [Line Items]
Warrant exercise price		$ 0.0001
Warrant Liability [Member]
Class Of Stock [Line Items]
Shares issued for common stock at-the-market, net of issuance costs	$ 69,414
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Shares issued for common stock at-the-market, net of issuance costs, shares	7,250,000	2,265,115
Sale price	$ 4.76
Warrants to purchase	19,000,000
Warrant exercise price	$ 5.95	$ 5.95
Shares issued for common stock at-the-market, net of issuance costs	$ 21,025
Issuance costs incurred on registered offering	$ 1,197	$ 552
Class 2 Common Stock [Member] | Minimum [Member]
Class Of Stock [Line Items]
Warrants expire period	6 months
Class 2 Common Stock [Member] | Maximum [Member]
Class Of Stock [Line Items]
Warrants expire period	5 years
Class 2 Common Stock [Member] | Pre funded Warrants [Member]
Class Of Stock [Line Items]
Sale price	$ 4.7599
Warrants to purchase	11,750,000	11,750,000
Warrant exercise price	$ 0.0001	$ 0.0001

Registered Offering and Warra_2

Registered Offering and Warrants - Schedule of Pre-funded Warrants and Warrants Outstanding (Detail)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrant issued	30,750,000
Warrant exercised	(11,750,000)
Ending Balance	19,000,000
Pre funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant description	Pre-Funded Warrants
Warrant classification	Liability
Warrant exercise price | $ / shares	$ 0.0001
Warrant expiration date	Mar. 17, 2025
Warrant issued	11,750,000
Warrant exercised	(11,750,000)
Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant description	Warrants
Warrant classification	Liability
Warrant exercise price | $ / shares	$ 5.95
Warrant expiration date	Mar. 17, 2025
Warrant issued	19,000,000
Ending Balance	19,000,000

Registered Offering and Warra_3

Registered Offering and Warrants - Schedule of Estimated Fair Value of Warrant Liability (Detail) - Warrant [Member] - Level 3 [Member]	Mar. 31, 2020USD ($)yr
Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0.0094
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	1.18
Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input | yr	5.5
Expected Dividend Yield [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0
Strike Price [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	5.95
Fair Value of Common Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	6.88
Discount Due to Exercise Restrictions [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0.17

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Capital Stock (Detail)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Class 1 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, par value | $ / shares	$ 0.0001
Common stock, shares authorized | shares	250,000,000
Common stock voting rights	10 votes for each share
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, par value | $ / shares	$ 0.0001
Common stock, shares authorized | shares	500,000,000
Common stock voting rights	1 vote for each share
Preferred Stock [Member]
Class Of Stock [Line Items]
Convertible preferred stock | $ / shares	$ 0.0001
Convertible preferred stock shares authorized | shares	10,000,000
Convertible preferred stock voting rights	N/A

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Capital Stock (Parenthetical) (Detail)	Mar. 31, 2020Vote
Class 1 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, votes for each share	10
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, votes for each share	1

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Mar. 17, 2020	Mar. 31, 2020
Class Of Stock [Line Items]
Warrants to purchase		19,000,000
Proceeds from issuance of common stock, gross	$ 85,289,000
Transaction costs recorded net against allocated gross proceeds in additional paid-in-capital	$ 5,150,000
Pre funded Warrants [Member]
Class Of Stock [Line Items]
Warrant exercise price		$ 0.0001
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Common stock issued, Shares	7,250,000	2,265,115
Warrant exercise price	$ 5.95	$ 5.95
Warrants to purchase	19,000,000
Proceeds from issuance of common stock, gross		$ 27,579,000
Transaction costs recorded net against allocated gross proceeds in additional paid-in-capital	$ 1,197,000	552,000
Maximum allowed aggregate gross proceeds from share issuance under ATM program		20,000,000
Maximum amount of share issuance allowed per quarter		$ 6,000,000
Class 2 Common Stock [Member] | Maximum [Member]
Class Of Stock [Line Items]
Warrant issue, price per share threshold limit		$ 11.90
Class 2 Common Stock [Member] | Pre funded Warrants [Member]
Class Of Stock [Line Items]
Warrant exercise price	$ 0.0001	$ 0.0001
Warrants to purchase	11,750,000	11,750,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Original Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expense	$ 162	$ 110
Unrecognized compensation expenses	$ 676
Unrecognized stock-based compensation expense to be recognized in period, years	9 months 18 days
Stock options granted	0	0
Fair values of stock option vested	$ 169	$ 95
2018 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expense	7,515	$ 5,626
Unrecognized compensation expenses	$ 58,318
Unrecognized stock-based compensation expense to be recognized in period, years	1 year 11 months 8 days
2018 Equity Incentive Plan [Member] | Time-based Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	0	10,000
Fair values of stock option vested	$ 25,426	$ 6,085
Weighted average fair values of stock options granted, per share	$ 0	$ 45.67
2018 Equity Incentive Plan [Member] | Performance-based Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	0	0
Fair values of stock option vested	$ 0	$ 955
2018 Equity Incentive Plan [Member] | Time-based RSU [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs granted	752,283	320,351
Number of RSUs vested	154,642	0
2018 Equity Incentive Plan [Member] | Performance-based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs granted	0	0
Number of RSUs vested	53,125	425,000
2018 Equity Incentive Plan [Member] | Class 2 common stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for issuance, annual automatic increase percentage	4.00%
2018 Equity Incentive Plan [Member] | Class 2 common stock [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock reserved for issuance, term	10 years
2018 Equity Incentive Plan [Member] | Class 2 common stock [Member] | Stock Options and Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares are reserved for issuance	17,037,421		12,926,172

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Original Stock Option Plan [Member]
Stock options
Shares, Beginning Balance	3,014,004
Shares, Granted	0	0
Shares, Exercised	(217,982)
Shares, Forfeited	(36,612)
Shares, Cancelled	(3,197)
Shares, Ending Balance	2,756,213		3,014,004
Shares, Vested and expected to vest	2,742,644
Shares, Vested and exercisable	2,563,446
Weighted-average exercise price
Weighted-average exercise price, Beginning Balance	$ 3.04
Weighted-average exercise price, Exercised	0.27
Weighted-average exercise price, Forfeited	4.21
Weighted-average exercise price, Cancelled	4.44
Weighted-average exercise price, Ending Balance	3.20		$ 3.04
Weighted-average exercise price, Vested and expected to vest	3.18
Weighted-average exercise price, Vested and exercisable	$ 3
Weighted-average remaining contractual term (years)
Weighted-average remaining contractual term	5 years 7 months 6 days		5 years 9 months 18 days
Weighted-average remaining contractual term, Vested and expected to vest	5 years 7 months 6 days
Weighted-average remaining contractual term, Vested and exercisable	5 years 4 months 24 days
Aggregate intrinsic value
Aggregate intrinsic value	$ 39,680		$ 44,108
Aggregate intrinsic value, Vested and expected to vest	39,525
Aggregate intrinsic value, Vested and exercisable	$ 37,319
2018 Equity Incentive Plan [Member] | Time-based Stock Options [Member]
Stock options
Shares, Beginning Balance	5,307,130
Shares, Granted	0	10,000
Shares, Exercised	(169,817)
Shares, Forfeited	(95,340)
Shares, Cancelled	(5,596)
Shares, Ending Balance	5,036,377		5,307,130
Shares, Vested and expected to vest	4,863,171
Shares, Vested and exercisable	2,707,014
Weighted-average exercise price
Weighted-average exercise price, Beginning Balance	$ 14.04
Weighted-average exercise price, Exercised	7.76
Weighted-average exercise price, Forfeited	17.04
Weighted-average exercise price, Cancelled	62.32
Weighted-average exercise price, Ending Balance	14.14		$ 14.04
Weighted-average exercise price, Vested and expected to vest	13.93
Weighted-average exercise price, Vested and exercisable	$ 12.29
Weighted-average remaining contractual term (years)
Weighted-average remaining contractual term	8 years 1 month 6 days		8 years 4 months 24 days
Weighted-average remaining contractual term, Vested and expected to vest	8 years 1 month 6 days
Weighted-average remaining contractual term, Vested and exercisable	8 years 1 month 6 days
Aggregate intrinsic value
Aggregate intrinsic value			$ 44,297
2018 Equity Incentive Plan [Member] | Performance-based Stock Options [Member]
Stock options
Shares, Beginning Balance	520,000
Shares, Granted	0	0
Shares, Ending Balance	520,000		520,000
Shares, Vested and expected to vest	520,000
Shares, Vested and exercisable	520,000
Weighted-average exercise price
Weighted-average exercise price, Beginning Balance	$ 7.76
Weighted-average exercise price, Ending Balance	7.76		$ 7.76
Weighted-average exercise price, Vested and expected to vest	7.76
Weighted-average exercise price, Vested and exercisable	$ 7.76
Weighted-average remaining contractual term (years)
Weighted-average remaining contractual term	8 years 1 month 6 days		8 years 4 months 24 days
Weighted-average remaining contractual term, Vested and expected to vest	8 years 1 month 6 days
Weighted-average remaining contractual term, Vested and exercisable	8 years 1 month 6 days
Aggregate intrinsic value
Aggregate intrinsic value			$ 4,872

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of RSU Activity (Detail) - 2018 Equity Incentive Plan [Member] - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Time-based RSU [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share equivalent, Beginning Balance	1,423,392
Share equivalent, Granted	752,283	320,351
Share equivalent, Vested	(154,642)	0
Share equivalent, Forfeited	(186,454)
Share equivalent, Ending Balance	1,834,579
Weighted-average grant date fair value, Beginning Balance	$ 42.05
Weighted-average grant date fair value, Granted	11.20
Weighted-average grant date fair value, Vested	55.92
Weighted-average grant date fair value, Forfeited	45.27
Weighted-average grant date fair value, Ending Balance	$ 27.90
Performance-based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share equivalent, Beginning Balance	265,625
Share equivalent, Granted	0	0
Share equivalent, Vested	(53,125)	(425,000)
Share equivalent, Ending Balance	212,500
Weighted-average grant date fair value, Beginning Balance	$ 7.76
Weighted-average grant date fair value, Vested	7.76
Weighted-average grant date fair value, Ending Balance	$ 7.76

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive (Loss) Income (AOCI) - Schedule of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 9,719
Change in foreign currency translation	(16,633)	$ (475)
Change in unrealized losses on available-for-sale debt securities	(74)
Ending balance	(6,988)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	10,021
Change in foreign currency translation	(16,633)
Ending balance	(6,612)
Unrealized (Loss) Gain on Available-for-sale Debt Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(302)
Change in unrealized losses on available-for-sale debt securities	(74)
Ending balance	$ (376)

Commitments and Contingencies -

Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail) $ in Thousands	Mar. 31, 2020USD ($)
Operating leases
2020 (remaining nine months)	$ 2,799
2021	3,025
2022	2,944
2023	2,844
2024	2,443
Thereafter	7,801
Total lease payments	21,856
Imputed interest	3,161
Obligations recognized	18,695
Finance leases
2020 (remaining nine months)	614
2021	798
2022	5,686
2023	11,545
Total lease payments	18,643
Imputed interest	5,430
Obligations recognized	$ 13,213

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Non-cancellable Minimum Purchase Commitments (Detail) $ in Thousands	Mar. 31, 2020USD ($)
Purchase Commitment Excluding Longterm Commitment [Line Items]
Total	$ 113,047
2020 (remaining nine months)	111,445
2021	1,530
2022	36
2023	36
Purchase Commitments [Member]
Purchase Commitment Excluding Longterm Commitment [Line Items]
Total	113,047
2020 (remaining nine months)	111,445
2021	1,530
2022	36
2023	$ 36

Commitments and Contingencies_3

Commitments and Contingencies - Additional Information (Detail) - Rose Lifescience, Inc [Member]	12 Months Ended
	Dec. 31, 2018USD ($)kg
Long Term Purchase Commitment [Line Items]
Maximum quantity of purchase commitment | kg	2,000
Purchase commitment price based on cost of goods sold percentage	115.00%
Cannabis [Member]
Long Term Purchase Commitment [Line Items]
Purchase commitment percentage	40.00%
Distribution and Marketing [Member]
Long Term Purchase Commitment [Line Items]
Commitment Term	5 years
Distribution and Marketing [Member] | Minimum [Member]
Long Term Purchase Commitment [Line Items]
Minimum commitment Fee | $	$ 384,000

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Other Commitments Maturities (Detail) $ in Thousands	Mar. 31, 2020USD ($)
Other Commitments [Line Items]
Total	$ 651,188
2020 (remaining nine months)	49,591
2021	34,251
2022	64,096
2023	500,250
2024	1,500
Thereafter	1,500
ABG Finance Liability [Member]
Other Commitments [Line Items]
Total	8,000
2020 (remaining nine months)	500
2021	1,500
2022	1,500
2023	1,500
2024	1,500
Thereafter	1,500
Convertible Notes, Principal and Interest [Member]
Other Commitments [Line Items]
Total	570,000
2020 (remaining nine months)	23,750
2021	23,750
2022	23,750
2023	498,750
Senior Facility, Principal and Interest [Member]
Other Commitments [Line Items]
Total	55,765
2020 (remaining nine months)	7,918
2021	9,001
2022	38,846
Portugal Construction Commitments [Member]
Other Commitments [Line Items]
Total	17,423
2020 (remaining nine months)	$ 17,423

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Detail)	3 Months Ended
	Mar. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Revenue From Contract With Customer [Abstract]
Number of reportable segments | Segment	2
Contract balances in the balance sheets | $	$ 0	$ 0

General and Administrative Ex_3

General and Administrative Expenses - Schedule of General and Administrative Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
General And Administrative Expense [Abstract]
Salaries	$ 7,296	$ 6,411
Professional fees	4,521	2,457
Travel expenses	963	721
Other expenses	4,493	2,698
Credit loss expenses	46	536
Loss on disposal of property and equipment	457	111
Total	$ 17,776	$ 12,934

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Noncash Or Part Noncash Acquisitions [Line Items]
Cash paid for interest	$ 704	$ 73
Non-cash financing activities
Shares issued for employee compensation		649
Manitoba Harvest [Member]
Non-cash investing
Acquisition of Manitoba Harvest, Natura		195,407
Natura [Member]
Non-cash investing
Acquisition of Manitoba Harvest, Natura		38,980
Investment In ABG [Member]
Non-cash investing
Investment in ABG Profit Participation Arrangement, net of receivable		$ 94,805

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 854	$ 247
Operating cash flows from finance leases	142
Financing cash flows from finance leases	105
Non-cash additions to Right-of-use assets and lease liabilities
Operating leases	$ 423	$ 3,431

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Annual lease payments	$ 21,856
Accounts payable to related party	$ 748	$ 68
Cannfections [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%		50.00%
Fluent [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%		50.00%
Ten Eleven [Member]
Related Party Transaction [Line Items]
Annual lease payments	$ 470
Sub-leases expiration period	Dec. 31, 2020
Joint Venture [Member] | Cannfections [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%
Percentage of voting interest	50.00%
Joint Venture [Member] | Fluent [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%
Percentage of voting interest	50.00%
General and Administrative Expense [Member] | Aircraft Time Share Reimbursement [Member]
Related Party Transaction [Line Items]
Payment for use of aircraft	$ 261	0
General and Administrative Expense [Member] | Leafly Holdings, Inc [Member]
Related Party Transaction [Line Items]
Operational expenses	129	0
General and Administrative Expense [Member] | Docklight L L C
Related Party Transaction [Line Items]
Management service fees expense	221	59
General and Administrative Expense [Member] | Ten Eleven [Member]
Related Party Transaction [Line Items]
Management service fees expense	53	50
Other Income, Net [Member] | Ten Eleven [Member]
Related Party Transaction [Line Items]
Sublease income	$ 118	$ 0

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Financial Instruments [Abstract]
Change in exchange rate	10.00%
Carrying value of net asset	$ 25,465
Canadian prime rate	8.05%
Convertible notes, fixed interest rate	5.00%
Change in Canadian prime rate	1.00%
Loss due to one percentage change in Canadian prime rate	$ 44

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Assets Measured Fair Value on Recurring Basis (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Measurements, Recurring [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Acquisition-related contingent consideration	$ (393,000)	$ (420,000)
Warrant liability	(92,339)
Total recurring fair value measurements	(85,714,000)	8,810,000
Fair Value, Measurements, Recurring [Member] | Equity Investments Measured at Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	1,838,000	4,183,000
Fair Value, Measurements, Recurring [Member] | Debt Securities Classified as Available-for-Sale [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	5,180,000	5,047,000
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total recurring fair value measurements	2,477,000	4,910,000
Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Equity Investments Measured at Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	1,838,000	4,183,000
Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Debt Securities Classified as Available-for-Sale [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	639,000	727,000
Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Acquisition-related contingent consideration	(393,000)
Warrant liability	(92,339)
Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Acquisition-related contingent consideration	(393,000)	(420,000)
Warrant liability	(92,339)
Total recurring fair value measurements	(88,191,000)	3,900,000
Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Debt Securities Classified as Available-for-Sale [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	$ 4,541,000	$ 4,320,000

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Opening Balances of Assets and Liabilities Categorized Within Level 3 of the Fair Value Hierarchy Measured at Fair Value on a Recurring Basis (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Debt securities classified as available-for-sale, Beginning Balance	$ 4,320
Debt securities classified as available-for-sale, Interest expenses, net	221
Debt securities classified as available-for-sale, Ending Balance	4,541
Acquisition- related contingent consideration, Beginning Balance	(420)
Acquisition- related contingent consideration, Foreign currency translation gain, net	27
Acquisition- related contingent consideration, Ending Balance	(393)
Warrant liability, Additions	(69,414)
Warrant liability, Exercise	49,053
Warrant liability, Change in fair value of warrant liability	(71,978)
Warrant liability, Ending Balance	$ (92,339)

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Quantitative Information about Level 3 Fair Value Measurements (Detail)	Mar. 31, 2020USD ($)yr	Dec. 31, 2019USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of, Debt securities classified as available-for-sale	$ 5,180,000	$ 5,047,000
Quantitative information about Level 3 Fair Value Measurements [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of, Debt securities classified as available-for-sale	$ 4,541,000
Debt Securities, Available-for-sale, Valuation Technique [Extensible List]	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Acquisition-related contingent consideration	$ (393,000)
Business Combination, Contingent Consideration, Liability, Valuation Technique [Extensible List]	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Warrant liability	$ (92,339)
Warrants and Rights Outstanding, Valuation Technique [Extensible List]	tlry:ValuationTechniqueMonteCarloMember
Quantitative information about Level 3 Fair Value Measurements [Member] | Discount Due to Exercise Restrictions [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Debt securities classified as available-for-sale, Range	16.5
Acquisition-related contingent consideration, Range	15
Quantitative information about Level 3 Fair Value Measurements [Member] | Probability of Conversion/ Prepayment [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Debt securities classified as available-for-sale, Range
Quantitative information about Level 3 Fair Value Measurements [Member] | Probability of Default [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Debt securities classified as available-for-sale, Range
Quantitative information about Level 3 Fair Value Measurements [Member] | Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input	118
Quantitative information about Level 3 Fair Value Measurements [Member] | Restriction [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input	17
Quantitative information about Level 3 Fair Value Measurements [Member] | Minimum [Member] | Assumed Likelihood of Milestone Payments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration, Range	50
Quantitative information about Level 3 Fair Value Measurements [Member] | Minimum [Member] | Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input | yr	0.5
Quantitative information about Level 3 Fair Value Measurements [Member] | Maximum [Member] | Assumed Likelihood of Milestone Payments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration, Range	90
Quantitative information about Level 3 Fair Value Measurements [Member] | Maximum [Member] | Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input | yr	5.5
Quantitative information about Level 3 Fair Value Measurements [Member] | Weighted Average [Member] | Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input | yr	2.5

Business Segment Information -

Business Segment Information - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2020USD ($)Segment	Mar. 31, 2019USD ($)	Dec. 31, 2019
Segment Reporting Information [Line Items]
Number of operating segment | Segment	2
Revenue	$ 52,102,000	$ 23,038,000
Customer Concentration Risk [Member] | Revenue [Member] | Customer A [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	26.00%	13.00%
Customer Concentration Risk [Member] | Revenue [Member] | Customer B [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	16.00%
Customer Concentration Risk [Member] | Revenue [Member] | Customer C [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	13.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer A [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	18.00%		20.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer B [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	12.00%		10.00%
Intersegment Sales or Transfers [Member]
Segment Reporting Information [Line Items]
Revenue	$ 0

Business Segment Information _2

Business Segment Information - Summary of Revenue and Gross Profit of each Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 52,102	$ 23,038
Gross profit	10,870	5,385
Cannabis [Member]
Segment Reporting Information [Line Items]
Revenue	30,776	17,456
Gross profit	2,926	3,621
Hemp [Member]
Segment Reporting Information [Line Items]
Revenue	21,326	5,582
Gross profit	$ 7,944	$ 1,764

Business Segment Information _3

Business Segment Information - Summary of Revenue and Gross Profit (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting [Abstract]
Gross profit for the segments	$ 10,870	$ 5,385
General and administrative expenses	17,776	12,934
Sales and marketing expenses	17,876	7,821
Research and development expenses	1,258	1,048
Depreciation and amortization expenses	3,591	1,865
Stock-based compensation expenses	7,677	5,736
Impairment of assets	29,839
Acquisition-related expenses, net	2,355	4,424
Loss from equity method investments	1,748
Foreign exchange loss, net	28,069	179
Change in fair value of warrant liability	71,978
Interest expenses, net	9,146	8,744
Finance income from ABG		(135)
Other expense (income), net	4,651	(3,845)
Loss before income taxes	$ (185,094)	$ (33,386)

Business Segment Information _4

Business Segment Information - Summary of Sources of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 52,102	$ 23,038
Dried Cannabis [Member]
Segment Reporting Information [Line Items]
Revenues	19,696	10,936
Cannabis Extracts [Member]
Segment Reporting Information [Line Items]
Revenues	10,545	6,454
Hemp Products [Member]
Segment Reporting Information [Line Items]
Revenues	21,326	5,582
Accessories And Other [Member]
Segment Reporting Information [Line Items]
Revenues	$ 535	$ 66

Business Segment Information _5

Business Segment Information - Summary of Channels of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 52,102	$ 23,038
Cannabis [Member]
Segment Reporting Information [Line Items]
Revenue	30,776	17,456
Cannabis [Member] | Adult-use [Member]
Segment Reporting Information [Line Items]
Revenue	20,919	7,880
Cannabis [Member] | Canada - medical [Member]
Segment Reporting Information [Line Items]
Revenue	4,051	2,998
Cannabis [Member] | International - medical [Member]
Segment Reporting Information [Line Items]
Revenue	5,806	1,811
Cannabis [Member] | Bulk [Member]
Segment Reporting Information [Line Items]
Revenue		4,767
Hemp [Member]
Segment Reporting Information [Line Items]
Revenue	$ 21,326	$ 5,582

Business Segment Information _6

Business Segment Information - Summary of Revenues Attributed to a Geographic Region Based on the Location of the Customer (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 52,102	$ 23,038
CANADA [Member]
Segment Reporting Information [Line Items]
Revenues	29,488	17,002
UNITED STATES [Member]
Segment Reporting Information [Line Items]
Revenues	16,530	4,225
Other Countries [Member]
Segment Reporting Information [Line Items]
Revenues	$ 6,084	$ 1,811

Business Segment Information _7

Business Segment Information - Summary of Long-lived Assets Consisting of Property, Plant and Equipment, Net of Accumulated Depreciation, Attributed to Geographic Regions Based On Their Physical Location (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 186,970	$ 184,217
CANADA [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	131,915	144,065
Portugal [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	50,069	36,908
UNITED STATES [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	4,824	3,171
Other Countries [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 162	$ 73

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Thousands, $ in Thousands	Jun. 03, 2020USD ($)	Jun. 03, 2020CAD ($)	Apr. 01, 2020USD ($)	Mar. 25, 2020shares	Feb. 28, 2020	Mar. 31, 2020USD ($)
Subsequent Event [Line Items]
Severance Costs						$ 1,861
Senior Secured Term Loan Facility [Member] | High Park Holdings Ltd. [Member]
Subsequent Event [Line Items]
Frequency of repayment					monthly
Class 2 Common Stock [Member] | Former Equity Holders of Privateer Holdings, Inc. [Member]
Subsequent Event [Line Items]
Common stock, shares released | shares				11,000,000
Subsequent Event [Member] | Senior Secured Term Loan Facility [Member] | High Park Holdings Ltd. [Member]
Subsequent Event [Line Items]
Line of credit additional amount drawn	$ 9,900	$ 13,300
Transaction fees on additional draw	567	798
Increase in principal repayment amount	$ 83	$ 111
Frequency of repayment	monthly	monthly
Line of credit facility, expiration date	Feb. 28, 2022	Feb. 28, 2022
Cannabis [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Severance Costs			$ 466